Simvastatin suppresses experimental aortic aneurysm expansion  by Kalyanasundaram, Arun et al.
From the Society for Vascular Surgery
Simvastatin suppresses experimental aortic
aneurysm expansion
Arun Kalyanasundaram, MD, MPH, James R. Elmore, MD, James R. Manazer, MD, Alicia Golden, BS,
David P. Franklin, MD, Spencer W. Galt, MD, Emad M.A. Zakhary, MD, and David J. Carey, PhD,
Danville, Pa
Objective: Abdominal aortic aneurysm (AAA) formation is a result of inflammation and extracellular matrix (ECM)
remodeling mediated by matrix metalloproteinases (MMPs). Hydroxymethylglutaryl-coenzyme A inhibitors (statins),
although clinically used as lipid-lowering agents, have also been demonstrated to have anti-inflammatory effects. This
study was designed to determine whether the hydroxymethylglutaryl-coenzyme A inhibitor simvastatin suppresses
aneurysm formation in an elastase-induced rat AAA model.
Methods: Aneurysms were created in adult male Wistar rats by infusion of elastase into isolated infrarenal aortic segments.
The rats were randomized to receive either simvastatin (n  17) or placebo (n  17) by gastric lavage daily starting the
day before surgery. The rats were euthanized and the infrarenal aortas harvested on postoperative day 7. Aortic diameters
were measured before infusion, immediately after infusion, and at the time of harvesting. Protein expression was
measured by immunoblot analysis. Gene expression profiling using Affymetrix U34A rat genome chips was performed to
identify changes in gene expression caused by simvastatin treatment.
Results: Mean aneurysm diameter was significantly less in the simvastatin treatment group compared with controls (3.4
 0.08 mm vs 4.3  0.19 mm; P  .0001). MMP-9 and nuclear factor-B protein levels were decreased in the aortas of
simvastatin-treated animals. Gene microarray analysis revealed 315 genes with statistically significant changes in
expression (P < .05) in the simvastatin group. Genes related to inflammation, ECM remodeling, and oxidative stress
function were downregulated. These included genes for interleukin 1, interleukin 4, inducible nitric oxide synthase,
P-selectin, platelet-derived growth factor , tumor necrosis factor, and several chemokines.
Conclusions: Simvastatin significantly suppresses experimental aneurysm expansion and reduces protein levels of MMP-9
and nuclear factor-B. Gene array analysis provides evidence that several mediators of inflammation, matrix remodeling,
and oxidative stress are downregulated by simvastatin treatment. This suggests that simvastatin inhibits AAA formation
by blocking the expression of certain proinflammatory genes. Simvastatin may be useful as an adjuvant therapy to
suppress the growth of small aneurysms. (J Vasc Surg 2006;43:117-124.)
Clinical Relevance: Human aortic aneurysms are characterized histologically by an inflammatory infiltrate with severe
proteolytic destruction. Statins, although used clinically as lipid-lowering agents, have been shown to have anti-
inflammatory effects. Simvastatin reduced experimental aneurysm size in this study. It seems that this reduction is
mediated by interfering with multiple pathways, including oxidative stress, inflammation, and ECM and matrix
remodeling. Further study into the effect of statins in reducing the growth of AAAs in patients is warranted.Investigation into the pathophysiology of abdominal
aortic aneurysms (AAAs) has focused on inflammation as
playing a critical role in the development of AAA. There-
fore, drugs that decrease inflammation could be of poten-
tial benefit to patients with aneurysms. The objective of
these treatments would be to stabilize aneurysmal disease
and prevent further expansion, thus delaying or eliminating
the need for surgery.
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doi:10.1016/j.jvs.2005.08.007The rat aneurysm model is an established method of
creating experimental aortic aneurysms by intra-aortic in-
fusion of porcine pancreatic elastase. Aneurysm develop-
ment in this rat model is associated with production of
inducible nitric oxide synthase (iNOS),1 increased expres-
sion of matrix metalloproteinase (MMP)-9,1,2 an inflam-
matory infiltrate,2,3 and destruction of extracellular matrix
(ECM).1-4 Agents that block these activities have been
shown to suppress the expansion of experimental aneu-
rysms.1,5-7
Hydroxymethylglutaryl-coenzyme A reductase inhibi-
tors, also known as statins, are widely prescribed for their
lipid-lowering effects. In addition, statins have specific ef-
fects on inflammation. Statins have been shown to block
the activation of nuclear factor (NF)-B, a transcription
factor involved in the activation of gene expression during
inflammation.8 Statins also inhibit the expression of iNOS
and several MMPs, including MMP-9, by smooth muscle
cells and macrophages.9 These effects of statins might be
attributed to interference with the protein isoprenylation
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inflammation.10 Statins can directly modulate the biology
of the AAA wall in humans and can suppress MMP-9
production by inhibiting the activation of neutrophils and
macrophages; this indicates that statin therapy could be an
effective treatment for AAA patients.11
The evidence supporting an inflammatory cause of
aortic aneurysms and the effects on NF-B, iNOS, and
MMP-9 produced by statins in cell studies prompted us to
investigate the effects of statins on experimental AAAs. We
also performed a gene array analysis in an attempt to
elucidate the mechanism of action of statins on aneurysm
formation.
METHODS
Animal surgery, aortic infusion, and drug
administration. Experimental aortic aneurysms were cre-
ated in adult male Wistar rats (240-340 g) by infusion of
elastase as described previously,12 as modified by our labo-
ratory.5,13 With rats under isoflurane anesthesia, a midline
laparotomy was performed, and the infrarenal aorta was
dissected. Lumbar arterial branches in this region were
ligated. After proximal and distal ties were secured, a mat-
tress stitch was placed in the anterior aorta. The isolated
infrarenal aorta was then cannulated with a 27-gauge nee-
dle and infused with 1 mL (22 U/mL) of porcine pancre-
atic elastase solution (Sigma Chemical Co, St Louis, Mo)
for 1 hour with a microinfusion pump (Harvard Apparatus,
Holliston, Mass). The needle was then removed, the mat-
tress stitch was tied, and blood flowwas restored to the legs.
The fascia was sutured, and skin wounds were stapled. The
rats were allowed to recover, were individually housed, and
were provided with standard rat chow and water ad libitum.
The rats underwent repeat exploration on postoperative
day 7. Measurements of aortic diameter were made with an
ocular micrometer with 0.1-mm gradations at 10 power
mounted on the operating microscope. Animal care com-
plied with the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources, Com-
mission on Life Sciences, and National Research Council).
The study was approved by the Institutional Animal Care
and Use Committee.
Before surgery, rats were randomized into experimen-
tal (n 19) and control (n 19) groups. The investigators
were blinded to treatment. All treatments were started the
day before the operation and were administered via gastric
lavage with an animal feeding needle. The control group
received tap water (1 mL/d), and the treatment group
received simvastatin (60 mg · kg1 · d1 in 1 mL of water).
Dosing was repeated daily until harvest. The dose of sim-
vastatin was comparable to doses used in previous studies in
rats.14,15
Seventeen rats per group survived to postoperative day
7. Two animals died from anesthesia, and two were eutha-
nized on postoperative day 1 because of hind limb isch-
emia. All remaining rats were euthanized on postoperative
day 7 after repeat exploration. Measurements of maximal
aortic diameter were recorded before elastase infusion,immediately after elastase infusion, and before aortic har-
vest on postoperative day 7. Rats that did not survive to
harvest were excluded, and the randomization schedule was
adjusted by animal care personnel. All harvested aortic
segments were flash-frozen in liquid nitrogen. Individual
specimens were then used for histological, biochemical, or
microarray analysis in sequential order.
Histology. Aortic segments were fixed with 10% for-
malin solution and embedded in paraffin. Sections were
stained with hematoxylin-eosin and elastin-orcein (eight
control and eight simvastatin-treated specimens). The
slides were viewed with a Nikon microscope equipped with
a digital camera. Inflammation and elastin preservation
were quantitated on hematoxylin-eosin–stained and elastin-
stained slides, as described previously.5
Western blot analysis. Samples from simvastatin-
treated and control rats were homogenized in extraction
buffer containing 1% Triton X-100. Aliquots were sub-
jected to sodium dodecyl sulfate gel electrophoresis on 7.5
polyacrylamide gels and transferred to polyvinylidene diflu-
oride membranes at 70 V. Membranes were blocked for 1
hour with 5% nonfat powdered milk and incubated over-
night with primary antibodies. Primary antibodies used
included NF-B p65 rabbit polyclonal (1:500 dilution;
Santa Cruz Biotechnology, Santa Cruz, Calif) and mouse
monoclonal anti–MMP-9 (clone Ab-5, 1:250 dilution; Lab
Vision Corporation, Fremont, Calif). The lower portions of
all blots were incubated with mouse monoclonal anti–-
actin (1:500 dilution; Sigma) to verify equivalent gel load-
ing. Themembranes were then incubated for 30minutes in
the appropriate secondary antibody and processed for en-
hanced chemiluminescence. Chemiluminescence was de-
tected and quantitated with the Lumi-imager (Boehringer
Mannheim, Indianapolis, Ind). Signal intensities for
MMP-9 and NF-B bands were normalized by using the
-actin signal for each sample.
RNA extraction and microarray analysis. Total
RNA was isolated from aortic samples by using TRIzol
reagent (Invitrogen-Life Technologies, Carlsbad, Calif) ac-
cording to the supplied protocol. The yield of RNA was
determined by the measuring the absorbance at 260 and
280 nm. RNA samples were further purified by using the
RNeasy Mini Kit (Qiagen, Valencia, Calif). For each sam-
ple, 10 g of RNA was used to synthesize complementary
DNA with an oligo-dT (deoxythymidine) primer contain-
ing the T7 polymerase promoter sequence. An in vitro
transcription reaction was used to generate biotin-labeled
chromosomal RNA from the complementary DNA tem-
plate. The chromosomal RNA was fragmented, and an
agarose gel was run to verify the sizes of the RNA frag-
ments. A hybridization cocktail was then prepared by using
20 g of fragmented chromosomal RNA. The cocktail was
hybridized to a Rat GenomeU34A array (Affymetrix, Santa
Clara, Calif) at 45°C for 18 hours. Next, the cocktail was
removed, and the arrays were washed and incubated with
R-Streptavidin-Phycoerythrin (Molecular Probes, Eugene,
Ore). The signal was amplified with a biotinylated anti-
streptavidin antibody (Vector Laboratories, Burlingham,
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by following standard Affymetrix protocols. The results
were analyzed with the GeneChip Operating Software 2.1
(Affymetrix) and Spotfire Decision Site 8.1 (Spotfire, Som-
erville, Mass).
Quantitative reverse transcriptase-polymerase chain re-
action (RT-PCR) was performed by using a Quantitect
SYBR Green RT-PCR kit (Qiagen) according to the man-
ufacturer’s protocol. Reactions were prepared by using 100
ng of RNA isolated as previously described. RT-PCR anal-
ysis was performed by using a Roche Molecular Biochemi-
cals Lightcycler, software version 3.5 (Roche, Pleasanton,
Calif).
Statistical analysis. The preinfusion, postinfusion,
and final diameters for the experimental and control groups
were recorded, and means and standard errors were calcu-
lated. Data were analyzed by using the Student t test. The
percentage increase of aortic diameter was defined as
[(day 7 aortic diameter  postinfusion aortic diame-
ter)/postinfusion aortic diameter]  100
A P value of .05 was considered significant.
Affymetrix GeneChip Operating Software 2.1 was used
to make standard adjustments for artifacts, noise, and back-
ground and to calculate a detection P value for each gene
on each array. These data were imported into a spreadsheet,
where they were sorted by the detection call. All gene
probes scored as present or marginal on two or more of the
arrays in one of the groups were selected for further analy-
sis. These data were imported into Spotfire Decision Site
8.1 for further analysis. The data set was normalized by first
scaling each experiment by mean followed by z score cal-
culation of the gene probes. The resulting data were then
analyzed using a one-way analysis of variance test to deter-
mine which genes were significantly changed. A P value of
.05 was considered significant. The Spotfire software was
then used to cluster the experiments (columns) and gene
probes (rows) into a heat map by using the unweighted
average and Euclidean distance methods.
RESULTS
Aneurysm size. Rats were randomly assigned to re-
ceive either simvastatin or control (water) treatment. Iso-
lated segments of rat abdominal aortas were infused with
porcine pancreatic elastase to induce AAA formation. A
total of 34 rats survived to postoperative day 7, when the
animals were euthanized. Perioperative mortality was 11%
(two rats in the control group and two rats in the simvas-
tatin-treated group). The preinfusion aortic sizes in control
rats (1.7  0.04 mm) and simvastatin-treated rats (1.7 
0.03 mm) were not statistically different (P  .83). The
immediate postinfusion diameters for control (2.2  0.05
mm) and simvastatin-treated (2.1  0.04 mm) rats were
not significantly different (P  .63) between groups. On
postoperative day 7, the mean aortic diameters were statis-
tically different between the control and simvastatin
groups. Control rats had a mean aortic diameter 4.3 0.19
mm, and simvastatin-treated rats had a mean aortic diame-
ter of 3.4  0.08 mm (P  .0001). The increase in aorticdiameter over postinfusion values was 93% 9% in control
animals and 59%  5% in simvastatin-treated animals (P 
.0012; Fig 1). The difference between preinfusion and day
7 diameters was significant in both groups (P  .0001).
Tissue histologic characteristics. The effects of sim-
vastatin treatment on gross inflammation and tissue archi-








































Fig 1. Effects of simvastatin on aneurysm expansion. (Top)Aortic
diameters for control rats and simvastatin-treated rats before elas-
tase infusion, immediately after elastase infusion, and on postop-
erative day 7. Simvastatin significantly inhibited aneurysm expan-
sion on postoperative day 7 as compared with controls (P 
.0001). (Bottom) The percentage increase in aortic diameter was
calculated as described in Methods and was significantly less in
simvastatin-treated rats (P  .0012).stained and orcein-elastin–stained sections of aneurysms
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iments failed to identify statistically significant differences
in the scoring of elastin preservation and inflammatory cell
infiltration between the two experimental groups (data not
shown). These results suggest that inflammatory cell infil-
tration of the tissue was not affected by simvastatin treat-
ment.
MMP-9 and NF-B expression. Several studies have
implicated increased MMP-9 expression in aneurysm for-
mation. MMP-9 steady-state levels in the aortas of control
and simvastatin-treated animals were determined by immu-
noblot analysis. As shown in Fig 2, simvastatin treatment
caused a 64% decrease in MMP-9 levels compared with
controls (P  .05). The decrease in MMP-9 expression in
simvastatin-treated animals was confirmed by quantitative
polymerase chain reaction (PCR) analysis (data not
shown).
NF-B levels were also decreased 54% in the simvasta-
tin group compared with the control group as determined
by immunoblot analysis (P  .05; Fig 2). This decrease was
also confirmed by quantitative PCR analysis (data not
shown). The reduced steady-state levels of MMP-9 and
NF-B relative to -actin levels indicate that these reduc-
tions do not reflect reduced aneurysm size.
Gene expression profiling. To obtain additional in-
formation on the mechanism by which simvastatin treat-
ment suppressed aneurysm formation, RNA isolated from
aortas of simvastatin-treated and control animals was used
for gene expression profiling by using Affymetrix U34A rat
gene chips. Out of the 8879 genes represented on the
chips, 315 genes showed significant differences in expres-
sion (P  .05; n  3 per treatment group). Of these, 80%
showed decreased expression in simvastatin-treated sam-
ples, and 20% showed increased expression (see the online
supplement for the complete microarray expression data,
including cluster analysis of all genes with significantly
altered expression [Fig 3, online only], a heat map and list
of oxidative genes with altered expression [Fig 4, online
only], and a detailed list of significantly altered genes [Ta-
ble I, online only]. Descriptions of gene probes in Table I
[online only] can be found at www.affymetrix.com).
Of particular interest was the large number of simvastatin-
downregulated genes that are involved in inflammation or
immune system function, ECM synthesis and remodeling,
and oxidative stress. Thirty-eight genes with inflammation/
immune function showeddecreased expression in simvastatin-
treated animals. These included several gene products that
promote inflammation, such as chemokines, the leukocyte
adhesion molecules P-selectin and integrin 	M, a tumor ne-
crosis factor family member, and interleukin 1 and interleukin
8 receptors (Fig 5). Nineteen genes related to ECM synthesis
or remodeling were downregulated in simvastatin-treated an-
imals. These included the ECMproteins fibronectin, tenascin
C, and collagen type III, and the collagen-processing enzymes
procollagen lysine hydroxylase and prolyl-4-hydroxylase. Pro-
teins involved in ECM remodeling, such as MMP-3, tissue
inhibitor of metalloproteinase I, and tissue plasminogen acti-
vator, were also downregulated (Fig 6). MMP-9 expressionmeasured on the microarrays was lower in simvastatin-treated
samples, but this did not reach statistical significance (P .1).
Genes related to oxidative stress have been reported to be
upregulated during experimental aneurysm formation.16 Sim-































Fig 2. Western blot analysis of matrix metalloproteinase
(MMP)-9 and nuclear factor (NF)-B. Lysates of aortas from
control animals and simvastatin-treated animals were subjected to
Western blot analysis with anti–MMP-9 and anti–NF-B antibod-
ies. The upper panels show representative Western blots. The bar
graphs show means and standard errors. Expression levels for
MMP-9 and NF-B were decreased in simvastatin-treated tissue
(P  .05).stress-related genes, including thioredoxin reductase, super-
is fac
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(Fig 4, online only). The results of microarray analysis were
confirmed by quantitative PCR for iNOS and rapamycin-
binding protein (data not shown).
DISCUSSION
The pathophysiology of human AAA formation is com-
plex and involves multiple factors, such as biomechanical
wall stress, inflammation, proteolytic degradation, and ge-
netics.2,17 Effective medical therapy to slow the growth of
aortic aneurysmal disease would be of tremendous benefit
tomany patients with AAAs. Themost important finding of
this study is that simvastatin reduced experimental aneu-
rysm size. Statins have revolutionized the management of
atherosclerosis. Data from many large, randomized, multi-
center clinical trials have now established a clear role for
statins in both primary and secondary prevention of coro-
nary artery disease. The pleiotropic effects of statins,
namely, the non–lipid-lowering effects of statin therapy,
have been increasingly recognized in recent years.
The National Cholesterol Education Program, with
the endorsement of the American Heart Association, has
Fig 5. Microarray data for genes related to inflammation
the heat map colors. Red indicates increased expression;
a single aortic sample. All genes listed showed a signi
(P  .05). LPS, Lipopolysaccharide; TNF, tumor necrosdetermined that AAA harbors a coronary heart disease risksimilar to that of peripheral arterial disease and carotid
artery disease.18 The recommendation is to initiate drug
therapy in these patients to achieve target low-density
lipoprotein levels in order to reduce their risk of coronary
heart disease. As a consequence of this recommendation by
the AmericanHeart Association, many AAA patients will be
placed on statin therapy. Our findings suggest that statin
treatment of AAA patients could have the added benefit of
reducing their rate of aneurysm expansion.
The pathophysiology of aneurysm formation in the rat
elastase model is multifactorial. Aneurysm formation is not
dependent on the initial infusion of elastase activity, but
rather on the subsequent inflammatory response andmatrix
remodeling caused by products released by macrophages
and other inflammatory cells.13 The animal model has also
been used to identify therapeutic interventions that might
suppress aneurysm formation. Thus, our laboratory has
shown that inhibitors of MMP activity,7 inhibitors of iNOS
activity,1 and the immunosuppressor drug rapamycin5 sup-
press expansion of experimental aneurysms.
In this study, simvastatin suppressed aneurysm expan-
sion compared with controls. Simvastatin had no effect on
immune function. Gene expression levels are reflected in
indicates decreased expression. Each column represents
decrease in expression in simvastatin-treated animals
tor; Ig, immunoglobulin.and
green
ficantinflammatory cell infiltration into the tissue, yet biochemi-
resen
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decreased. This suggests that statins mediate their effects, at
least partially, by blocking inflammatory signaling cascades.
This is consistent with other studies that have shown the
anti-inflammatory activity of statins.8-11 Nagashima et
al11showed that treatment with cerivastatin suppressed
MMP-9 production by neutrophils and macrophages in
AAA tissues but did not affect the extent of inflammation,
and these findings are consistent with the findings in this
study. In our previous study with the immunosuppressor
rapamycin, we did not find a quantitative difference in
inflammatory cell infiltration, despite a significant reduc-
tion in aneurysm size. A recent report also demonstrated
suppression of experimental aneurysm formation by simva-
statin in mice. This effect was independent of the lipid-
lowering effects of the statin,19 thus suggesting that the
reduction in aneurysm size reported here was not caused by
changes in serum lipid levels.
NF-B is a nuclear transcription factor thought to be
one of the primary modulators of inflammatory signaling.20
In our experiment, NF-B steady-state levels were de-
creased in simvastatin-treated AAA tissue by immunoblot
analysis. NF-B is induced by various cytokines, particularly
interleukin 1 and tumor necrosis factor 	. NF-B can
stimulate the production of multiple proinflammatory
compounds, including iNOS and interleukin 1. Nakashima
et al21 have shown that NF-B suppression reduces exper-
imental aneurysm expansion. Inhibition of NF-B has been
associated with decreased production ofMMP-9 in vascular
smooth muscle cells.22 This is consistent with our finding
that MMP-9 levels were decreased in simvastatin-treated
Fig 6. Microarray data for genes related to extracellula
levels are reflected in the heat map colors.Red indicates in
column represents a single aortic sample. All genes liste
treated animals (P  .05). Note that some genes are reprats.Inflammation plays a key role in the pathogenesis of
aneurysms.3,13,21 Previous studies have shown increased
expression of genes related to inflammation, such as cyto-
kines, cyclooxygenase 2, and iNOS, in AAAs.16,23,24 The
gene expression profiling data reported here support the
biochemical and histologic analyses and strongly suggest
that simvastatin suppresses aneurysm expansion by modu-
lating inflammatory signaling pathways. Several proinflam-
matory gene products were downregulated by simvastatin,
including cytokines, chemokines and their receptors, and
leukocyte adhesion molecules. Other inflammation-related
genes that were significantly decreased in the statin group
included gene products involved in acute phase reactions,
mediators of inflammatory pathway signaling, and sub-
stances that enhance monocyte/macrophage and neutro-
phil chemotaxis and activation.25-35
Expansion of aneurysms is directly related to remodel-
ing of the ECM, mediated in part by active proteolysis.36
Expression of members of the MMP family of secreted
proteases, which are produced by macrophages, is upregu-
lated in aneurysm formation.16,23 In this study, we demon-
strated that simvastatin treatment caused downregulation
of MMP-9 and MMP-3 expression. Tissue plasminogen
activator and plasminogen activator inhibitor 1 were also
downregulated. Several genes related to ECM biosynthesis
were also downregulated, including fibronectin, collagen
type III 	1, and collagen-processing enzymes.
Oxidative stress has been suggested to contribute to the
tissue damage associated with aneurysm expansion. Induc-
ible NOS expression is induced during aneurysm formation
in the animal model37-39 and in human disease.40 Nitric
trix (ECM) synthesis and remodeling. Gene expression
ed expression; green indicates decreased expression. Each
wed a significant decrease in expression in simvastatin-
ted by multiple probes.r ma
creas
d shooxide, the product of iNOS, can mediate oxidative degra-
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Inhibition of iNOS activity limits experimental aneurysmal
expansion.39 iNOS expression was downregulated by sim-
vastatin treatment (Fig 5). This downregulation is likely to
be beneficial and to contribute to suppressing aneurysm
expansion. Simvastatin also caused downregulation of
other oxidative gene products, including heme oxygenase,
which releases carbon monoxide during heme metabolism
and has been suggested to contribute to aneurysm forma-
tion by oxidative tissue injury.16 Other potentially impor-
tant oxidative stress–related genes that were downregulated
by the statin were thioredoxin reductase 1 and superoxide
dismutase.
CONCLUSION
Simvastatin significantly suppresses experimental aneu-
rysm expansion and reduces protein levels of MMP-9 and
NF-B. Gene array analysis provides evidence that several
mediators of inflammation, matrix remodeling, and oxida-
tive stress are downregulated by simvastatin treatment. This
suggests that simvastatin inhibits AAA formation by block-
ing the expression of certain proinflammatory and oxidative
stress genes. Simvastatin may be useful as an adjuvant
therapy to suppress the growth of small aneurysms.
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ence in expression in simvastatin-treated animals (P  .05).
.05).
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Volume 43, Number 1 Kalyanasundaram et al 117.e9Fig 3. online only. Cluster analysis of genes with statistically
significant differences in expression. Gene expression levels are
reflected in the heat map colors. Red indicates increased expres-
sion; green indicates decreased expression. Each column represents
a single aortic sample. All genes listed showed a significant differ-Fig 4. online only. Microarray data for genes related to oxidative stress. Gene expression levels are reflected in the
heat map colors. Red indicates increased expression; green indicates decreased expression. Each column represents a
single aortic sample. All genes listed showed a significant decrease in expression in simvastatin-treated animals (P 
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X66370_at 3920.7 P 4098.6 P 5010 P 3612.3 P 3637.1 P 3721.6 P
rc_H31588_at 39.9 P 50.1 P 45.5 A 17.6 A 22.6 A 28.3 P
M13011cds_at 117.6 P 138 P 147 A 84.9 P 101.4 P 99.1 P
X76453_at 82.5 P 102.5 P 116.8 P 20.8 P 29.4 P 50.1 P
X60328_g_at 35.6 P 38.9 P 48.5 A 13.5 A 20.7 A 21.3 A
AB011365_s_at 48.9 P 66.5 P 84.8 P 16.1 M 31.3 P 37.9 P
rc_AA894264_at 77 P 81.9 P 103.3 M 42.6 A 56.1 A 67.5 P
X14181cds_s_at 5694.1 P 6173 P 7332.3 P 4744 P 5060.5 P 5446.4 P
X56228_at 99.7 P 142.5 P 178.2 P 70.9 P 89.3 P 76 P
X70223_at 34.4 P 52.1 P 60 A 18.8 M 21.7 A 21.1 A
D17521_at 49.3 P 63.4 P 81.2 A 35.6 P 36.6 P 34.1 P
rc_AI070783_at 34.1 P 56.1 P 67.6 P 17.2 P 15.9 P 25.5 P
rc_AI170568_s_at 132.6 P 192.6 P 215.6 P 102.1 P 111.8 P 118.8 P
J02585_at 57.2 P 135.7 P 221.3 P 22.8 P 8.5 A 19.7 M
AF055286_at 8.1 P 13.1 P 22.8 A 2.5 A 3.9 A 5.7 A
rc_AA800202_at 24.5 P 31.6 P 43.9 P 16.3 P 18.9 P 20.1 P
D31838_at 30.4 P 34.9 P 48.2 A 21.1 M 23.4 M 23.2 P
M77694_at 64.9 P 80.4 P 147.6 P 37.2 P 38.9 P 45.2 P
rc_AA800243_at 63.7 P 74.4 P 143 P 33.3 P 37.5 P 34.3 P
D14014_g_at 145.4 P 159.4 P 214.6 P 120.9 P 114.4 P 131.5 P
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Descriptions t-test/Anova Gene Title
X66370 R.norvegicus mRNA for ribosomal protein S9 /
cds(26,610) /gbX66370 /gi57142 /ugRn.3381
/len688
0.008306593 ribosomal protein S9




M13011cds RATRASH1C Rat c-ras-H-1 gene, complete
cds
0.0385477 Similar to Transforming protein p21/H-Ras-1
(c-H-ras)
X76453 R.norvegicus (Sprague Dawley) H-rev107 mRNA
/cds(97,579) /gbX76453 /gi433962
/ugRn.11377 /len966
0.004669983 HRAS like suppressor
X60328 R.norvegicus mRNA for cytosolic epoxide
hydrolase /cds(0,317) /gbX60328 /gi55929 /
ugRn.11415 /len637
0.002422969 epoxide hydrolase 2, cytoplasmic
AB011365 Rattus norvegicus mRNA for PPAR-gamma
protein, complete cds
0.021881602 peroxisome proliferator activated receptor,
gamma
rc_AA894264 EST198067 Rattus norvegicus cDNA, 3 end
/cloneRSPAU21 /clone_end3 /gbAA894264 /
gi3021143 /ugRn.24883 /len583
0.034542989 Similar to kIAA0367
X14181cds RRRPL18A Rat mRNA for ribosomal protein
L18a
0.046100929 similar to 60S ribosomal protein L18a
X56228 Rat mRNA for rhodanese /cds(0,887)
/gbX56228 /gi57068 /ugRn.6360 /len999
0.033061442 Thiosulfate sulfurtransferase
X70223 R. norvegicus mRNA for 22kDa integral
peroxisomal membrane protein /cds(17,601)
/gbX70223 /gi297436 /ugRn.10292 /len852
0.010022217 peroxisomal membrane protein 2
D17521 RATCLC3 Rat mRNA for protein kinase C-
regulated chloride channel, complete cds
0.007878614 Chloride channel 3
rc_AI070783 UI-R-C2-mr-c-08-0-UI.s1 Rattus norvegicus




rc_AI170568 EST216501 Rattus norvegicus cDNA, 3 end
/cloneRMUAY05 /clone_end3 /gbAI170568
/gi3710608 /ugRn.4005 /len670
0.040584079 dodecenoyl-coenzyme A delta isomerase
J02585 Rat liver stearyl-CoA desaturase mRNA, complete
cds /cds(102,1178) /gbJ02585 /gi206859
/ugRn.10982 /len4689
0.038050208 stearoyl-Coenzyme A desaturase 1
AF055286 Rattus norvegicus potential-sensitive
polyspecific organic cation transporter OCT3 (OCT3)
mRNA, complete cds
0.039697302 solute carrier family 22, member 3




D31838 RATWEE1 Rat mRNA for wee1 tyrosine kinase,
complete cds
0.007175213 —
M77694 R.norvegicus fumarylacetoacetate hydrolase
(FAH) mRNA, complete cds /cds(22,1281)
/gbM77694 /gi204089 /ugRn.9195 /len1373
0.039701547 fumarylacetoacetate hydrolase
rc_AA800243 EST189740 Rattus norvegicus cDNA, 3 end
/cloneRHEAM86 /clone_end3 /gbAA800243
/gi2863198 /ugRn.8171 /len613
0.032262363 Similar to cell death activator CIDE-A
D14014 RATCYCLD1 Rat mRNA for cyclin D1, complete 0.012502237 cyclin D1
cds
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U70211_at 106.1 P 139.3 P 177.7 P 64.3 A 101.9 A 76.9 P
X14210cds_g_at 5963.6 P 6519.7 P 7441.1 P 4949.6 P 3531.9 P 5122.9 P
rc_AI232374_g_at 355.6 P 355.4 P 427.8 P 225.6 P 207.1 P 228.1 P
rc_AA891737_at 49.1 P 55.6 P 60.8 P 29.6 P 22.5 P 25.5 P
S65091_g_at 11.9 P 15.7 P 17.4 A 3.4 A 1 A 5.4 A
AF055286_g_at 40.7 P 51.4 P 48.3 A 7.3 A 4 A 13.3 A
U16686_at 35.7 P 45.7 P 36.9 A 10 A 4.1 A 14.1 A
rc_AA799537_at 67.8 P 78.9 P 92.9 A 58.4 P 47.4 A 52 P
rc_AA818888_at 4742.7 P 5219.3 P 6452.1 P 4609.1 P 4181.3 P 4065.7 P
M24105_at 163.2 P 221.5 P 206.4 P 131.1 P 127.8 P 123.1 P
X97772_g_at 95.1 P 175.2 P 134.8 P 54.7 P 50.2 P 54.5 P
rc_AA799560_at 201.8 P 314.3 P 273.8 P 112.3 P 125.1 P 142 P
U17013_at 44.2 P 57.9 P 61.3 P 37.1 P 38.2 P 35.1 P
J04591_at 18.9 P 22.5 P 25.2 A 14.7 P 15.8 A 14 P
rc_AA942685_at 557 P 893.4 P 422.2 P 73.3 P 54 P 178.4 P
rc_AI045440_at 79 P 105.9 M 75.9 A 49.4 P 24.6 A 37.7 P
rc_AA799410_g_at 57.4 P 54.5 P 84.2 A 45.2 P 39.1 A 31.1 A
rc_AA800678_g_at 520.7 P 501.7 P 700 P 451.2 P 407.9 P 354.3 P
rc_AI639199_at 41.3 P 38.8 P 62.7 A 28.2 P 31 P 26.3 P
rc_AA875633_at 825.9 P 915.8 P 1361.6 P 697.6 P 711.3 P 541.2 P
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X14210cds RNRPS4 Rat mRNA for ribosomal protein S4 0.04531494 Ribosomal protein S4, X-linked
rc_AI232374 EST229062 Rattus norvegicus cDNA, 3 end
/cloneRKICA88 /clone_end3 /gbAI232374 /
ugRn.3129 /len609
0.000133257 H1 histone family, member 0
rc_AA891737 EST195540 Rattus norvegicus cDNA, 3 end
/cloneRKIAG17 /clone_end3 /gbAA891737 /
gi3018616 /ugRn.3650 /len558
0.00109138 —
S65091 cyclic AMP-regulated phosphoprotein [rats,
mRNA, 1030 nt]
0.003071975 Similar to protein phosphatase 1, regulatory
(inhibitory) subunit 1C; thymocyte ARPP
AF055286 Rattus norvegicus potential-sensitive
polyspecific organic cation transporter OCT3 (OCT3)
mRNA, complete cds
0.001788858 solute carrier family 22, member 3
U16686 Rattus norvegicus defensin RatNP-1 precursor
mRNA, complete cds /cds(76,360) /gbU16686
/gi1041810 /ugRn.10223 /len485
0.007862358 defensin, alpha 5, Paneth cell-specific




rc_AA818888 UI-R-A0-av-c-08-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-A0-av-c-08-0-UI
/clone_end3 /gbAA818888 /gi2888474
/ugRn.4300 /len504
0.031751045 ubiquitin A-52 residue ribosomal protein
fusion product 1
M24105 Rat vesicle associated membrane protein (VAMP-
2) mRNA, complete cds /cds(20,370) /gbM24105
/gi207626 /ugRn.11289 /len2071
0.04970358 vesicle-associated membrane protein 2




rc_AA799560 EST189057 Rattus norvegicus cDNA, 3 end
/cloneRHEAC55 /clone_end3 /gbAA799560
/gi2862515 /ugRn.3407 /len604
0.030926479 N-myc downstream-regulated gene 2
U17013 Rattus norvegicus transcription factor Oct1
(Oct1) mRNA, partial cds /cds(0,1898)
/gbU17013 /gi575454 /ugRn.9992 /len2157
0.033877806 POU domain, class 2, transcription factor 1
J04591 Rat dipeptidyl peptidase IV (DPP) mRNA,
complete cds /cds(88,2391) /gbJ04591
/gi203973 /ugRn.1862 /len4835
0.010506465 dipeptidylpeptidase 4
rc_AA942685 EST198184 Rattus norvegicus cDNA, 3 end
/cloneRBRAA17 /clone_end3 /gbAA942685
/gi3102601 /ugRn.2589 /len620
0.04103323 cytosolic cysteine dioxygenase 1
rc_AI045440 UI-R-C1-jz-a-12-0-UI.s2 Rattus norvegicus












Rat mixed-tissue library Rattus norvegicus cDNA clone
rx02840 3 , mRNA sequence [Rattus norvegicus]
0.017953937 —
rc_AA875633 UI-R-E0-ct-f-03-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-E0-ct-f-03-0-UI
/clone_end3 /gbAA875633 /gi2980581
0.040567688 —/ugRn.2983 /len415
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rc_H33486_at 38.9 P 44.4 P 62.5 A 33 P 22.4 A 32.3 P
AFFX-BioB-3_at 135.2 P 128.7 P 225.6 P 101.4 P 60.4 P 81.2 P
X57405_g_at 198.4 P 201.2 P 296 P 175 P 155.1 P 169.9 P
AFFX-BioC-5_at 489.6 P 413.9 P 847.7 P 290.1 P 225.7 P 246.6 P
rc_AA800593_at 60.6 P 49.3 P 97.7 P 30.5 P 26 P 37.3 P
rc_AI639001_at 89.3 P 75.6 P 123.6 P 62.7 P 53.8 P 67 P
rc_AI233749_at 965.9 P 851.3 P 1327.5 P 551.9 P 489.9 P 669 P
U72620_at 146.4 P 134.6 P 142.4 P 64.2 P 102 P 67 P
X95096_at 30.3 P 32.3 P 26.3 A 7.6 A 12.2 A 6 A
rc_AI176488_at 225.7 P 175.2 P 207 P 84.2 P 85.2 P 109.9 P
rc_AA800712_g_at 133.1 P 126.1 P 114.2 P 44.2 P 39.3 P 63.9 P
rc_AI105137_s_at 52.8 P 49.6 P 56.7 A 34.3 P 35.1 A 41.8 P
S81289_i_at 62.2 P 44.8 P 22.9 A 0.2 A 2.1 A 5.2 M
M83143_at 289.1 P 253.6 P 246.5 P 162 P 157.3 P 163.9 P
rc_AA874873_g_at 161.1 P 132.5 P 135 P 66.9 P 71.7 P 84 P
rc_AI233261_i_at 67.4 P 54.3 P 57.3 P 40.4 P 29.8 P 31.5 P
AFFX-BioB-M_at 447.5 P 399.2 P 450.6 P 293.6 P 142.5 P 205.1 P
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rc_H33486 EST109536 Rattus norvegicus cDNA, 3 end
/cloneRPNAS60 /clone_end3 /gbH33486
/gi978903 /ugRn.23316 /len395
0.030162982 Similar to hypothetical protein MGC28622
E. coli /GENbioB /DB_XREFgb:J04423.1
/NOTESIF corresponding to nucleotides 2755-3052
of gb:J04423.1 /DEFE.coli 7,8-diamino-pelargonic
acid (bioA), biotin synthetase (bioB), 7-keto-8-amino-
pelargonic acid synthetase (bioF), bioC protein, and
dethiobiotin synthetase (bioD), complete cds.
0.028604608 —
X57405 RRNOTCH R.rattus mRNA homologue of
Drosophila notch protein
0.028082155 Notch gene homolog 1, (Drosophila)
E. coli /GENbioC /DB_XREFgb:J04423.1
/NOTESIF corresponding to nucleotides 4218-4566
of gb:J04423.1 /DEFE.coli 7,8-diamino-pelargonic
acid (bioA), biotin synthetase (bioB), 7-keto-8-amino-
pelargonic acid synthetase (bioF), bioC protein, and
dethiobiotin synthetase (bioD), complete cds.
0.027315447 —




Rat mixed-tissue library Rattus norvegicus cDNA clone
rx02427 3 , mRNA sequence [Rattus norvegicus]
0.029626899 —
rc_AI233749 EST230437 Rattus norvegicus cDNA, 3 end
/cloneRKIDJ59 /clone_end3 /gbAI233749 /
ugRn.5971 /len462
0.008849427 ribosomal protein L30
U72620 Rattus norvegicus Lot1 mRNA, complete cds /
cds(547,2298) /gbU72620 /gi1621624
/ugRn.6977 /len4938
0.038078246 pleiomorphic adenoma gene-like 1
X95096 R.norvegicus mRNA for macrophage stimulating
protein /cds(12,2162) /gbX95096 /gi1669718
/ugRn.10613 /len2222
0.009694688 Macrophage stimulating 1 (hepatocyte growth
factor-like)
rc_AI176488 EST220073 Rattus norvegicus cDNA, 3 end
/cloneROVBS47 /clone_end3 /gbAI176488 /
ugRn.9909 /len650
0.013395196 nuclear factor I/B




rc_AI105137 EST214426 Rattus norvegicus cDNA, 3 end
/cloneRKIBG10 /clone_end3 /gbAI105137 /
gi3709294 /ugRn.3847 /len622
0.032264927 glutathione S-transferase, mitochondrial
S81289 IgM kappa chain variable region {CDR1 to CDR3
region} [rats, LEW, HAR-1 hybridoma cells, mRNA
Partial, 408 nt]
0.040462792 —
M83143 Rat beta-galactoside-alpha 2,6-sialyltransferase
mRNA /cds(104,748) /gbM83143 /gi203146
/ugRn.1409 /len3224
0.047609031 sialyltransferase 1
rc_AA874873 UI-R-E0-ci-d-11-0-UI.s1 Rattus norvegicus




rc_AI233261 EST229949 Rattus norvegicus cDNA, 3 end
/cloneRKIDC84 /clone_end3 /gbAI233261 /
ugRn.2460 /len629
0.048432976 glutamate cysteine ligase, modifier subunit
E. coli /GENbioB /DB_XREFgb:J04423.1
/NOTESIF corresponding to nucleotides 2482-2739
of gb:J04423.1 /DEFE.coli 7,8-diamino-pelargonic
acid (bioA), biotin synthetase (bioB), 7-keto-8-amino-
pelargonic acid synthetase (bioF), bioC protein, and
0.024919154 —dethiobiotin synthetase (bioD), complete cds.
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rc_AA799501_at 3199.6 P 2836.5 P 3643.7 P 2477 P 2374.1 P 2378.8 P
rc_H33461_at 104.6 A 72.1 P 108 P 46.4 P 53.7 P 57.3 P
X55153mRNA_s_at 4398.3 P 4104.1 P 5641.9 P 3342.5 P 3287.5 P 3262.3 P
M27905_at 2104.6 P 1697.7 P 2587.6 P 1625.6 P 1263.7 P 1201.7 P
rc_AI179027_at 97.2 P 91.7 P 120.8 A 86.3 P 78.9 A 83.3 A
AF009133_at 20.6 P 15.3 P 26.6 A 4.9 A 13 P 11.2 P
rc_AI176689_at 67.5 P 55.7 P 79.1 M 15.5 A 38.3 A 41.4 P
AB010119_at 99.9 P 103.6 P 179.2 P 190.7 P 161.2 P 187.4 P
L35767_at 39.7 P 37.2 P 60.4 A 53.2 P 49.3 M 51.3 P
rc_AI230778_at 347.5 P 299.3 P 451.8 P 393.2 P 389.3 P 399.6 P
AF090867_at 15.7 P 26.8 P 23.7 A 33.9 P 30.4 P 26.9 P
M64300_at 37.8 P 55.1 P 52.8 A 62.5 P 58.7 P 55.3 P
rc_AA875506_at 51.5 P 57.7 P 65.1 P 78.2 P 66.8 P 73.2 P
D10854_at 2118 P 2264.5 P 2893.1 P 2586 P 2398.1 P 2444.2 P
rc_AA799323_at 130.7 P 152 P 194.8 P 212.8 P 194.7 P 200.4 P
rc_AA818487_s_at 1792.1 P 1966.9 P 2501.3 P 2203.7 P 2201.2 P 2124.7 P
L13039_s_at 1621.6 P 2168.6 P 2979.4 P 2815.7 P 2852.2 P 2487.3 P
E03424cds_s_at 24 P 33 P 43.3 A 46.1 P 45.1 P 38.3 P
U23769_at 557.8 P 593.5 P 868 P 868.1 P 830.3 P 768.8 P
rc_AA893235_at 86.7 P 85.1 P 125 P 149 P 142.3 P 121.4 P
M18330_at 116.6 P 153 P 171 P 186.4 P 187.8 P 187.5 P
D89070cds_s_at 101.7 P 186.3 P 187.6 P 210.3 P 206.2 P 227.2 P
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rc_AA799501 EST188998 Rattus norvegicus cDNA, 3 end
/cloneRHEAB79 /clone_end3 /gbAA799501
/gi2862456 /ugRn.90 /len777
0.022214424 Ribosomal protein S4, X-linked
rc_H33461 EST109481 Rattus norvegicus cDNA, 3 end
/cloneRPNAS13 /clone_end3 /gbH33461
/gi978878 /ugRn.4252 /len551
0.033738296 oxidation resistance 1
X55153mRNA RRRP2G R.rattus RP2 gene for ribosomal
protein P2
0.00207503 Similar to 60S ACIDIC RIBOSOMAL
PROTEIN P2
M27905 Rattus norvegicus ribosomal protein L21 mRNA,
complete cds /cds(39,521) /gbM27905
/gi205118 /ugRn.2554 /len554
0.043385108 ribosomal protein L21
rc_AI179027 EST222709 Rattus norvegicus cDNA, 3 end
/cloneRSPCA64 /clone_end3 /gbAI179027 /
ugRn.119 /len545
0.022717461 —
AF009133 Rattus norvegicus CD94 (Cd94) mRNA,
complete cds /cds(262,801) /gbAF009133
/gi2267160 /ugRn.6025 /len1099
0.048083327 killer cell lectin-like receptor, subfamily D,
member 1
rc_AI176689 EST220282 Rattus norvegicus cDNA, 3 end
/cloneROVBV56 /clone_end3 /gbAI176689 /
ugRn.17256 /len597
0.033767425 mitogen-activated protein kinase kinase 6
AB010119 Rattus norvegicus mRNA for Tctex-1, complete
cds
0.010994893 t-complex testis expressed 1
L35767 Rat very low density lipoprotein receptor
(VLDLR) mRNA, complete cds /cds(183,2804) /
gbL35767 /gi532225 /ugRn.9975 /len2952
0.028322165 very low density lipoprotein receptor
rc_AI230778 EST227473 Rattus norvegicus cDNA, 3 end
/cloneREMDB16 /clone_end3 /gbAI230778
/ugRn.3659 /len560
0.023430541 Similar to tyrosylprotein sulfotransferase-2;
TPST-2
AF090867 Rattus norvegicus guanosine monophosphate
reductase mRNA, complete cds
0.046911705 guanosine monophosphate reductase
M64300 Rat extracellular signal-related kinase (ERK2)
mRNA, complete cds /cds(171,1247) /gbM64300
/gi204055 /ugRn.13651 /len1467
0.045919682 mitogen activated protein kinase 1
rc_AA875506 UI-R-E0-ct-c-05-0-UI.s1 Rattus norvegicus




D10854 Rat mRNA for aldehyde reductase, complete cds
/cds(53,1030) /gbD10854 /gi399659
/ugRn.835 /len1124
0.006603762 aldo-keto reductase family 1, member A1




rc_AA818487 UI-R-A0-at-d-09-0-UI.s1 Rattus norvegicus




L13039 RATANXIIA Rat annexin II mRNA, complete cds 0.040113004 annexin A2
E03424cds DNA encoding GTP cyclohydrolase I 0.026391043 GTP cyclohydrolase 1
U23769 Rattus norvegicus CLP36 (clp36) mRNA,
complete cds /cds(66,1049) /gbU23769
/gi1020150 /ugRn.11170 /len1392
0.008417395 PDZ and LIM domain 1
rc_AA893235 EST197038 Rattus norvegicus cDNA, 3 end
/cloneRKIBD88 /clone_end3 /gbAA893235 /
gi3020114 /ugRn.1040 /len645
0.0066072 Similar to G0S2-like protein
M18330 RATPKCDA Rat protein kinase C delta
subspecies
0.004301365 protein kinase C, delta
D89070cds Rattus norvegicus DNA for non-inducible 0.036603594 carbonyl reductase 1
carbony reductase, complete cds
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S50461_s_at 16.7 P 41.9 P 41 A 48.9 P 53.4 P 61.2 P
D28773_s_at 42.3 P 56.3 P 67.3 P 64 P 65.6 P 69.3 P
U94330_at 57.1 P 103.4 P 120.7 P 157.6 P 126.9 P 137.7 P
AA848268_at 21.1 A 35.3 P 46.1 A 48.5 P 42.8 P 48.7 P
U50185_g_at 54.9 P 68.5 P 86.2 P 83.9 P 74.5 P 85.7 P
S76779_s_at 5014.2 P 6903 P 9286.2 P 8413.8 P 8262.9 P 8350.3 P
rc_AA859806_at 376.5 P 427.3 P 529.8 P 448.8 P 440.5 P 448.7 P
rc_AA892562_g_at 144.4 P 131.3 P 180.9 P 154.3 P 155.1 P 179.6 P
rc_AI176595_s_at 1518.5 P 1307.9 P 1724.9 P 1703.5 P 1538.4 P 1923.4 P
rc_AI639343_at 14.5 P 8.8 P 10.8 A 22.7 A 18.5 A 28.9 P
Z22812_at 179.8 P 122.7 P 257.7 P 332.4 P 241 P 446.4 P
AF022081_at 85.7 P 84.2 P 55.4 A 114.1 P 123.3 P 179.5 P
X76988cds_at 27.5 P 30.7 P 28.3 A 41.2 P 49.9 P 61.2 P
Y00497_s_at 198.5 P 196.9 P 177.6 P 250 P 285.2 P 338.9 P
rc_AI236284_s_at 73.9 P 66.8 P 68.6 A 95.4 P 105.7 P 122.7 P
X99337cds_s_at 113.5 P 79 P 81 A 128.2 P 158.6 P 213.3 P
rc_AI231164_s_at 166.8 P 95.1 P 91.3 P 269.3 P 285.4 P 419.2 P
L11319_at 164 P 128.8 P 148.4 P 178.4 P 179.4 P 224.3 P
Y09507_at 154.9 P 70.9 P 64.7 P 165.3 P 293.4 P 338.9 P
E13732cds_at 85.6 P 81.7 P 106.2 P 130.6 P 194.7 P 257.3 P
AF084205_at 44.8 P 47.1 M 57.4 A 58.2 P 76.4 P 96.4 P
M62388_at 180.7 P 216.4 P 253.1 P 229.4 P 257.7 P 307.2 P
rc_AI639387_at 140.8 P 137.5 P 198.7 P 168.2 P 171.9 P 184.7 P
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S50461 G alpha 12z,signal-transducing G protein alpha
12 subunit [rats, brain, mRNA Partial, 466 nt]
0.033157591 guanine nucleotide binding protein, alpha 12
D28773 RATTXS Rat mRNA for thromboxane synthase,
complete cds
0.014494845 thromboxane A synthase 1
U94330 Rattus norvegicus osteoprotegerin (OPG) mRNA,
complete cds /cds(123,1328) /gbU94330
/gi2072180 /ugRn.9792 /len2432
0.02160626 tumor necrosis factor receptor superfamily,
member 11b (osteoprotegerin)
AA848268 EST191028 Normalized rat heart, Bento Soares
Rattus sp. cDNA clone RHEAC66 5 end similar to DnaJ
protein homolog 2, mRNA sequence [Rattus sp.]
0.028262002 Similar to mmDj4
U50185 RNU50185 Rattus norvegicus kidney protein
phosphatase 1 myosin binding subunit mRNA, partial
cds
0.017628872 protein phosphatase 1, regulatory (inhibitor)
subunit 12A




norvegicus cDNA, 3 end /cloneUI-R-E0-bu-h-11-0-
UI /clone_end3 /gbAA859806 /gi2949326 /
ugRn.771 /len460
0.018541265 —
rc_AA892562 EST196365 Rattus norvegicus cDNA, 3 end
/cloneRKIAS90 /clone_end3 /gbAA892562 /
gi3019441 /ugRn.4223 /len539
0.042703228 dyskeratosis congenita 1, dyskerin




Rat mixed-tissue library Rattus norvegicus cDNA clone
rx04036 3 , mRNA sequence [Rattus norvegicus]
0.020799915 —
Z22812 R.norvegicus interleukin-1 receptor type 2
/cds(123,1373) /gbZ22812 /gi311407
/ugRn.10758 /len1380
0.048523162 interleukin 1 receptor, type II
AF022081 Rattus norvegicus small nuclear RING finger
protein mRNA, complete cds
0.045214246 ring finger protein 4
X76988cds RNGALNACS R.norvegicus mRNA for gal
beta 1,3 galNAc alpha 2,3-sialyltransferase
0.01655521 sialyltransferase 4B (beta-galactoside alpha-
2,3-sialyltransferase)
Y00497 Rat mRNA for manganese-containing superoxide
dismutase (MnSoD) /cds(11,679) /gbY00497 /
gi56690 /ugRn.10488 /len1438
0.021235168 superoxide dismutase 2, mitochondrial
rc_AI236284 EST232846 Rattus norvegicus cDNA, 3 end
/cloneROVDD66 /clone_end3 /gbAI236284
/ugRn.2366 /len358
0.010541673 acyl-CoA synthetase long-chain family
member 4
X99337cds RNGP55 R.norvegicus mRNA for glycoprotein
55
0.044433011 stromal cell derived factor receptor 1
rc_AI231164 EST227852 Rattus norvegicus cDNA, 3 end
/cloneREMDG57 /clone_end3 /gbAI231164
/ugRn.8538 /len491
0.016737384 splicing factor, arginine/serine-rich 10
(transformer 2 homolog, Drosophila)
L11319 Rat signal peptidase mRNA, complete cds
/cds(74,613) /gbL11319 /gi206977
/ugRn.24875 /len643
0.042412648 signal peptidase complex 18kD
Y09507 R.norvegicus mRNA for hypoxia-inducible factor 1
/cds(123,2600) /gbY09507 /gi2924301
/ugRn.10852 /len2711
0.04540702 hypoxia inducible factor 1, alpha subunit
E13732cds cDNA encoding rat CC chemokine receptor
protein
0.036481013 macrophage inflammatory protein-1 alpha
receptor gene
AF084205 Rattus norvegicus serine/threonine protein
kinase TAO1 mRNA, complete cds
0.041806346 serine/threonine protein kinase TAO1
M62388 RATUCE Rattus norvegicus ubiquitin
conjugating enzyme mRNA, complete cds
0.042233965 ubiquitin conjugating enzyme
Rat mixed-tissue library Rattus norvegicus cDNA clone 0.011344241 Similar to mitochondrial ribosomal protein S6
rx05135 3 , mRNA sequence [Rattus norvegicus]
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M55017exon_s_at 45.2 P 41.8 P 55.9 A 52.8 P 67.5 P 69.8 P
AJ000557cds_s_at 26.9 P 24.6 P 37.3 A 49 P 65.7 P 73.7 P
rc_AI104500_at 90.8 P 86 P 101.3 M 124.1 P 159.3 P 158 P
rc_AA893022_at 319.4 P 321.5 P 450 P 428.7 P 475.7 P 467.2 P
rc_AI234060_s_at 879.2 P 383.4 P 141.9 P 1399 P 1106.3 P 1502 P
AF036537_g_at 257.4 P 175.6 P 165.1 P 338.8 P 284.5 P 322.3 P
rc_AA819793_at 81 P 74.1 P 86.9 P 84.3 P 82.3 P 88.9 P
M26594_at 44 P 30.1 P 27.2 A 52.1 P 49.6 P 54.9 P
rc_AI180288_s_at 220 P 146.5 P 93.1 P 280.8 P 267.7 P 307.6 P
M23566exon_s_at 398.1 P 357.2 P 406 P 522.6 P 476.5 P 543.2 P
M14656_at 2757.3 P 1892.4 P 1936.6 P 4289.5 P 3513.2 P 4561.4 P
M32062_g_at 747.7 P 513.9 P 581.9 P 930.8 P 1122.9 P 1032 P
U35890_at 117 P 56.4 P 54.7 A 138.1 P 187.3 P 178.5 P
D12770_s_at 1054.4 P 860.2 P 1084.1 P 1104 P 1172 P 1235.1 P
U36482_at 205.6 P 160.9 P 202.6 P 209.2 P 224.5 P 232 P
AB000778_s_at 140.1 P 88.5 P 136.5 P 160.4 P 165.8 P 168.1 P
X17053cds_s_at 633.1 P 203.6 P 337.6 P 706.9 P 786.7 P 801.6 P
E12625cds_at 56 P 52.7 P 64.9 A 85.2 P 67.8 P 84.4 P
U38253_at 48.5 P 51.3 P 57.7 A 66.8 P 56.2 P 69.7 P
L02121_at 55.2 P 57.1 P 67.2 A 80.2 P 66 P 83.4 P
AB003042_at 323.8 P 273.3 P 285.3 P 470.7 P 336.4 P 512 P
rc_AI639314_at 27.2 P 44.1 P 35.8 A 76.5 P 45.4 P 73.5 P
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M55017exon RATNUCIA2 Rat nucleolin gene 0.021446313 nucleolin
AJ000557cds RNJAK2 Rattus norvegicus mRNA for Janus
protein tyrosine kinase 2, JAK2
0.008153048 Janus kinase 2
rc_AI104500 EST213789 Rattus norvegicus cDNA, 3 end




rc_AA893022 EST196825 Rattus norvegicus cDNA, 3 end
/cloneRKIBB20 /clone_end3 /gbAA893022 /
gi3019901 /ugRn.4130 /len379
0.002719969 Similar to RIKEN cDNA 3110050F08




AF036537 Rattus norvegicus homocysteine respondent
protein HCYP2 mRNA, complete cds
0.03051962 receptor-interacting serine-threonine kinase 3
rc_AA819793 UI-R-A0-aq-f-03-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-A0-aq-f-03-0-UI
/clone_end3 /gbAA819793 /gi2888980
/ugRn.16664 /len522
0.042594288 Flap structure-specific endonuclease 1
M26594 Rat malic enzyme gene /cds(0,1760)
/gbM26594 /gi205293 /ugRn.22280
/len1761
0.035370276 malic enzyme 1
rc_AI180288 EST224031 Rattus norvegicus cDNA, 3 end
/cloneRSPCS84 /clone_end3 /gbAI180288 /
ugRn.10621 /len417
0.030957433 caldesmon 1
M23566exon RATA2MAC2 Rattus norvegicus alpha-2-
macroglobulin gene, 3 end
0.00468355 alpha-2-macroglobulin
M14656 Rat osteopontin mRNA, complete cds
/cds(79,1032) /gbM14656 /gi205859
/ugRn.8871 /len1457
0.010808436 secreted phosphoprotein 1
M32062 Rat Fc-gamma receptor mRNA, complete cds /
cds(49,852) /gbM32062 /gi204114
/ugRn.6050 /len1341
0.013091606 Fc receptor, IgG, low affinity III
U35890 Rattus norvegicus polypeptide GalNAc transferase
T1 mRNA, complete cds /cds(102,1781)
/gbU35890 /gi1141791 /ugRn.10266
/len1838
0.024948762 polypeptide GalNAc transferase T1
D12770 RATANT1 Rat mRNA for mitochondrial adenine
nucleotide translocator
0.028939972 solute carrier family 25 (mitochondrial
adenine nucleotide translocator) member 4
U36482 Rattus norvegicus endoplasmic reticulum protein
ERp29 precursor, mRNA, complete cds /cds(43,825)
/gbU36482 /gi2317799 /ugRn.11262
/len1115
0.044902526 endoplasmic retuclum protein 29
AB000778 Rattus norvegicus mRNA for phospholipase D,
complete cds /cds(195,3419) /gbAB000778
/gi2828349 /ugRn.11130 /len4945
0.024991954 phospholipase D1
X17053cds RATJE Rat immediate-early serum-responsive
JE gene
0.042530329 chemokine (C-C motif) ligand 2
E12625cds cDNA encoding a rat novel protein which is
expressed with nerve injury
0.007375029 sterol-C4-methyl oxidase-like
U38253 Rattus norvegicus initiation factor eIF-2B gamma
subunit (eIF-2B gamma) mRNA, complete cds
/cds(88,1446) /gbU38253 /gi1537014
/ugRn.10577 /len1470
0.013019815 eukaryotic translation initiation factor 2B,
subunit 3 (gamma, 58kD)
L02121 Rattus norvegicus (clone nclk) cdc2-related
protein kinase mRNA, complete cds /cds(93,971) /
gbL02121 /gi203389 /ugRn.10749 /len1161
0.010026143 cyclin-dependent kinase 5
AB003042 Rattus norvegicus mRNA for C5a receptor,
complete cds /cds(43,1101) /gbAB003042
/gi2116555 /ugRn.10680 /len1772
0.041934954 complement component 5, receptor 1
Rat mixed-tissue library Rattus norvegicus cDNA clone 0.038858844 Delangin
rx04757 3 , mRNA sequence [Rattus norvegicus]
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rc_AA894089_s_at 46.2 P 71.6 P 57.9 P 109.4 P 74.3 P 115.8 P
U62897_at 189.9 P 244.4 P 204.8 P 335.6 P 265.6 P 395.4 P
J02962_at 1876.7 P 2612.7 P 2088 P 3150.6 P 2739.4 P 3469.2 P
M11942_s_at 2680.3 P 2893.6 P 3847.2 P 4385.9 P 3174.6 P 3911.4 P
M89945mRNA_at 221.6 P 197.7 P 160.4 A 297.7 P 254.3 P 270.1 P
M17701_s_at 2162.5 P 2081.9 P 1497 P 2971.1 P 2648.2 P 2660.4 P
rc_AI171506_g_at 121.2 P 95.7 P 80.8 P 161.2 P 147.1 P 151.4 P
rc_AA875470_at 146.9 P 205.3 P 73.4 P 251.1 P 275.6 P 265.3 P
X53949cds_at 45.8 P 47.5 P 7.8 A 85.2 P 81.4 P 75.4 P
rc_AA859496_at 60.1 P 63.4 P 31.8 A 86.4 P 79.8 P 82.4 P
rc_AA875127_at 63.7 P 76.8 P 40.6 A 99.4 P 94.2 P 98.8 P
X74565cds_at 84.6 P 106.4 P 21.3 A 143.2 P 141.6 P 146.5 P
rc_AI145502_s_at 85.5 P 99.6 P 23.1 A 143.2 P 132 P 142.3 P
AB020504_at 27.7 P 27.9 M 24 A 32.8 P 32.8 A 34.9 P
X56729mRNA_at 35.5 P 37.5 P 26.8 A 55.4 P 46.8 P 55.3 P
AF030378_at 35 P 41.7 P 26.7 A 55.2 P 47.9 P 57.2 P
X73371_at 351.1 P 336.4 P 253.7 P 499.2 P 432.1 P 556.1 P
X12535cds_at 152.9 P 245.4 P 94.9 P 280.4 P 297.5 P 371.6 P
rc_AA875127_g_at 80.6 P 112.9 P 61.1 A 132.2 P 125.7 P 150.1 P
AB017188_at 142.7 P 159.3 P 164.5 P 166.6 P 168.6 P 193.5 P
rc_AA925246_at 593.2 P 818.2 P 753 P 1300.3 P 959 P 942.5 P
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rc_AA894089 EST197892 Rattus norvegicus cDNA, 3 end
/cloneRSPAQ63 /clone_end3 /gbAA894089 /
gi3020968 /ugRn.3736 /len613
0.033576793 praja 2, RING-H2 motif containing
U62897 Rattus norvegicus carboxypeptidase D precursor




J02962 Rat IgE binding protein mRNA, complete cds /
cds(40,828) /gbJ02962 /gi203173 /ugRn.764
/len948
0.028416325 lectin, galactose binding, soluble 3
M11942 RATHSPA Rat 70 kd heat-shock-like protein
mRNA, complete cds
0.039718652 heat shock protein 8
M89945mRNA RATFARDIPH Rat farnesyl diphosphate
synthase gene, exons 1-8
0.034801441 farensyl diphosphate synthase
M17701 RATGAPDHA Rat glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) mRNA, complete cds
0.037952753 glyceraldehyde-3-phosphate dehydrogenase
rc_AI171506 EST217469 Rattus norvegicus cDNA, 3 end
/cloneRMUBL83 /clone_end3 /gbAI171506
/gi3711546 /ugRn.6428 /len496
0.022330557 malic enzyme 1
rc_AA875470 UI-R-E0-cp-c-12-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-E0-cp-c-12-0-UI
/clone_end3 /gbAA875470 /gi2980418
/ugRn.2253 /len438
0.036731734 Similar to COP9 complex subunit 7a; COP9
subunit 7A
X53949cds RSGALEM Rat galE mRNA for UDP-
galactose 4-epimerase homologue (EC 5.1.3.2)
0.023461761 galactose-4-epimerase, UDP
rc_AA859496 UI-R-E0-bv-g-08-0-UI.s1 Rattus norvegicus





norvegicus cDNA, 3 end /cloneUI-R-E0-bu-d-05-0-
UI /clone_end3 /gbAA875127 /gi2980075 /
ugRn.18698 /len579
0.032986043 Similar to cell division cycle 2-like 5 isoform 1;
CDC2-related protein kinase 5
X74565cds RNTBFII R.norvegicus TBFII mRNA for
polypyrimidine tract binding protein
0.04404035 polypyrimidine tract binding protein 1
rc_AI145502 UI-R-BT0-qf-h-09-0-UI.s1 Rattus
norvegicus cDNA, 3 end /cloneUI-R-BT0-qf-h-09-0-
UI /clone_end3 /gbAI145502 /ugRn.6332 /
len443
0.04131259 prostaglandin F2 receptor negative regulator
AB020504 Rattus norvegicus mRNA for PMF31, complete
cds
0.036322804 PMF32 protein
X56729mRNA RSCALPST Rat mRNA for calpastatin 0.017722025 calpastatin
AF030378 Rattus norvegicus angiopoietin-2 mRNA,
partial cds
0.027547932 Angiopoietin-2
X73371 R.norvegicus mRNA for Fc gamma receptor
/cds(124,981) /gbX73371 /gi397576
/ugRn.10363 /len1430
0.023205774 Fc receptor, IgG, low affinity IIb
X12535cds RNRASP23 Rat mRNA for ras-related protein
p23
0.040834798 RAB7, member RAS oncogene family
rc_AA875127 UI-R-E0-bu-d-05-0-UI.s2 Rattus
norvegicus cDNA, 3 end /cloneUI-R-E0-bu-d-05-0-
UI /clone_end3 /gbAA875127 /gi2980075 /
ugRn.18698 /len579
0.040003726 Similar to cell division cycle 2-like 5 isoform 1;
CDC2-related protein kinase 5
AB017188 Rattus norvegicus mRNA for antisecretory
factor, complete cds
0.034699914 proteasome (prosome, macropain) 26S
subunit, non-ATPase, 4
rc_AA925246 UI-R-A1-eh-h-06-0-UI.s1 Rattus
norvegicus cDNA, 3 end /cloneUI-R-A1-eh-h-06-0-
UI /clone_end3 /gbAA925246 /gi3072382 /
0.034964542 cathepsin KugRn.5598 /len513
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rc_AI176461_s_at 50.1 P 92.2 P 31.5 A 120.7 P 101.4 P 105.5 P
AB006914_at 64.1 P 85.1 P 76.9 P 99.1 P 86.4 P 91.7 P
rc_AI058941_s_at 46.3 P 66.6 P 5.2 A 137.4 P 109.3 P 104 P
M25350_s_at 60.2 P 86.9 P 18.3 A 155.5 P 118.3 P 123 P
rc_AI044508_s_at 53.8 P 65.9 P 41.2 A 110.9 P 81.2 P 87.1 P
J04024_at 96.6 P 100.9 P 93.8 P 146.6 P 112 P 125.1 P
S69874_s_at 971.6 P 1003.2 P 890.5 P 1581.7 P 1185.1 P 1287.6 P
rc_AA800795_at 86.8 P 90.9 P 107 M 94.5 P 93 P 97.3 P
rc_AA891690_g_at 330.3 P 364.2 P 354 P 471 P 476.5 P 525.7 P
D38072_at 39.1 P 48.1 P 10 A 75.2 P 78.4 P 89 P
rc_AA875470_g_at 118.6 P 126.8 P 113.3 P 191.4 P 181 P 187.3 P
rc_AA944397_at 88 P 90.7 P 68.7 P 182.1 P 163.1 P 180 P
rc_AA818970_s_at 4.7 A 21.7 P 4.5 A 36.3 P 36.6 P 38.4 P
U75920_at 105.5 P 143.9 P 99 P 237.1 P 238.3 P 222.6 P
M15474cds_s_at 459.5 P 595.6 P 588 P 797.3 P 802.1 P 790.7 P
E12829cds_at 101.8 P 111.6 P 121.5 P 128.8 P 134.6 P 135.5 P
D49955_at 199.8 P 228.7 P 213 P 269.7 P 301.5 P 289.4 P
rc_AA900582_at 83.3 P 99.6 P 88 A 122.3 P 129.2 P 122.6 P
M34384_at 125.8 P 131.9 P 153.7 P 171.1 P 184.7 P 168.3 P
D90404_at 850 P 623.5 P 598 P 1655.5 P 2005.2 P 1745.8 P
U82612cds_at 129.2 P 137.8 P 56.5 A 512.4 P 506.5 P 447.8 P
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rc_AI176461 EST220046 Rattus norvegicus cDNA, 3 end
/cloneROVBS09 /clone_end3 /gbAI176461 /
ugRn.10507 /len534
0.049026954 golgi apparatus protein 1
AB006914 Rattus norvegicus mRNA for salt-tolerant
protein, complete cds /cds(48,1691) /gbAB006914
/gi2385507 /ugRn.10814 /len1946
0.036057233 thyroid hormone receptor interactor 10
rc_AI058941 UI-R-C1-lr-b-07-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-C1-lr-b-07-0-UI
/clone_end3 /gbAI058941 /ugRn.4231
/len476
0.018298159 dimethylarginine dimethylaminohydrolase 1
M25350 RATPHOCAMB Rat cAMP phosphodiesterase
(PDE4) mRNA, partial cds
0.026806516 phosphodiesterase 4B
rc_AI044508 UI-R-C1-kc-a-07-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-C1-kc-a-07-0-UI
/clone_end3 /gbAI044508 /ugRn.2865
/len372
0.027187353 neuron specific gene family member 1
J04024 Rat alternative brain Ca
2-ATPase mRNA,




 transporting, cardiac muscle,
slow twitch 2
S69874 C-FABPcutaneous fatty acid-binding protein
[rats, Sprague-Dawley, skin, mRNA, 704 nt]
0.030433 fatty acid binding protein 5, epidermal




rc_AA891690 EST195493 Rattus norvegicus cDNA, 3 end
/cloneRKIAF58 /clone_end3 /gbAA891690 /
gi3018569 /ugRn.22701 /len446
0.003654639 Tumor necrosis factor ligand superfamily
member 13 (A proliferation-inducing
ligand)
D38072 Rat mRNA for protein tyrosine phosphatase,
complete cds /cds(134,1282) /gbD38072
/gi567262 /ugRn.10707 /len1608
0.016256729 protein tyrosine phosphatase, non-receptor
type 12
rc_AA875470 UI-R-E0-cp-c-12-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-E0-cp-c-12-0-UI
/clone_end3 /gbAA875470 /gi2980418
/ugRn.2253 /len438
0.002287671 Similar to COP9 complex subunit 7a; COP9
subunit 7A
rc_AA944397 EST199896 Rattus norvegicus cDNA, 3 end
/cloneREMAG54 /clone_end3 /gbAA944397
/gi3104313 /ugRn.5916 /len542
0.001345559 heat shock protein 1, alpha
rc_AA818970 UI-R-A0-as-g-05-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-A0-as-g-05-0-UI
/clone_end3 /gbAA818970 /gi2888556
/ugRn.11412 /len616
0.008499791 endothelin receptor type B
U75920 RNAPCBP1 Rattus norvegicus APC binding
protein EB1 mRNA, complete cds
0.00280135 microtubule-associated protein, RP/EB
family, member 1
M15474cds RATTMA5 Rat alpha-tropomyosin gene, exon
11
0.001930443 tropomyosin 1, alpha
E12829cds cDNA encoding novel rat protein TIP120
which is formed of complex with TBP (TATA binding
protein)
0.002862258 TBP-interacting protein 120A
D49955 Rat mRNA for bone marrow stromal cell antigen
1 (BST-1), complete cds /cds(18,977) /gbD49955
/gi1255901 /ugRn.10728 /len1411
0.00976361 bone marrow stromal cell antigen 1
rc_AA900582 UI-R-E0-dn-b-10-0-UI.s1 Rattus
norvegicus cDNA, 3 end /cloneUI-R-E0-dn-b-10-0-
UI /clone_end3 /gbAA900582 /gi3035936 /
ugRn.780 /len495
0.008633928 alpha-2-macroglobulin




D90404 RATCATC Rat mRNA for cathepsin C 0.002000623 cathepsin C
U82612cds RNU82612 Rattus norvegicus fibronectin (fn- 0.000455997 fibronectin 1
1) gene, partial cds
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X94185cds_s_at 212.1 P 202.7 P 171.7 P 449.5 P 488.8 P 451.6 P
E13644cds_s_at 30.9 P 48 P 34 A 72.2 P 75.1 P 95.1 P
U35345_s_at 16.7 P 23.7 P 21.4 A 43.8 P 52.2 P 62.3 P
U82612cds_g_at 118.9 P 191.8 P 137.4 P 490.3 P 491.1 P 612.6 P
U70988cds_s_at 16.7 A 23.3 P 25.9 A 43.5 P 46.4 P 52.2 P
AJ006971_at 183.7 P 272.3 P 238.9 P 292.9 P 321.1 P 308.4 P
M86389cds_s_at 185.5 P 274.4 P 247.5 P 301.6 P 312.2 P 307.5 P
M21354_s_at 2564.5 P 4578.8 P 3238.4 P 4710.5 P 5037.9 P 5210.1 P
rc_AA799571_at 279.7 P 448.4 P 311.5 P 486.9 P 615.5 P 605.8 P
X07648cds_at 533.4 P 833.4 P 597.4 P 923.5 P 1068.6 P 1054.9 P
M96630_at 104.9 P 182.1 P 39.4 A 218.7 P 321.9 P 258.5 P
rc_AA799637_g_at 12.1 A 25 P 7.3 A 28.4 P 44.6 P 38.8 P
L09656_at 20.6 P 30.8 P 20.7 A 32.8 P 46 P 39.5 P
D84477_at 168.3 P 391.9 P 139.5 P 406.1 P 650.8 P 522.1 P
U83895_at 26 A 39.5 P 30.4 A 43.8 P 57.3 A 51.9 P
Z14118cds_g_at 11 A 24.5 P 16.7 A 25.1 P 37.6 P 36.4 P
rc_AA859648_at 92.1 P 112.2 P 130.8 A 117.3 P 160.4 P 145.1 P
U04740_at 25 P 39.7 P 36.8 A 53 P 77 P 69.8 P
U90448_at 104.7 P 196.4 P 210.5 P 301.9 P 428.8 P 385.3 P
M15358cds_at 370.8 P 624.8 P 86.2 P 1023.4 P 2393.6 P 1590.2 P
X95990exon_s_at 115.7 P 165.1 P 139.6 M 221.5 P 343.2 P 270 P
rc_AI170379_at 93.5 P 102.6 P 110.6 P 143 P 195 P 170.5 P
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X94185cds RNMKP3 R.norvegicus mRNA for dual
specificity phosphatase, MKP-3
0.00061484 dual specificity phosphatase 6
E13644cds cDNA encoding Neurodap-1 which is located
at the post-synaptic membrane thickening regions of
neurons and contains RING-H2 finger motif
0.007444941 praja 2, RING-H2 motif containing
U35345 Rattus norvegicus serine/threonine kinase
(gamma-PAK) mRNA, complete cds /cds(48,1622)
/gbU35345 /gi1016004 /ugRn.10116
/len1756
0.003944237 p21 (CDKN1A)-activated kinase 2
U82612cds RNU82612 Rattus norvegicus fibronectin (fn-
1) gene, partial cds
0.000999483 fibronectin 1
U70988cds RNU70988 Rattus norvegicus CXC
chemokine receptor (CXCR2) gene, complete cds
0.000800686 interleukin 8 receptor, beta
AJ006971 RNO6971 Rattus norvegicus mRNA for DAP-
like kinase
0.026929322 Death-associated like kinase
M86389cds RATHSP27A Rat heat shock protein (Hsp27)
mRNA, complete cds
0.024274807 heat shock 27kDa protein 1
M21354 RATCOL3A1 Rat collagen type III alpha-1
mRNA, partial cds
0.04894407 collagen, type III, alpha 1
rc_AA799571 EST189068 Rattus norvegicus cDNA, 3 end
/cloneRHEAC67 /clone_end3 /gbAA799571
/gi2862526 /ugRn.3458 /len541
0.026541151 Similar to RIKEN cDNA 1110001M20
X07648cds RNAG Rat mRNA for amyloidogenic
glycoprotein (rAG), cognate of human A4 amyloid
precursor protein
0.023547008 amyloid beta (A4) precursor protein
M96630 RATSEC61B Rattus rattus sec61 homologue
mRNA, complete cds
0.036655206 SEC61, alpha subunit (S. cerevisiae)
rc_AA799637 EST189134 Rattus norvegicus cDNA, 3 end
/cloneRHEAD45 /clone_end3 /gbAA799637
/gi2862592 /ugRn.25425 /len571
0.033698899 Similar to Golgi coiled coil protein GCC185
L09656 Rat salivary-specific cAMP response element-
binding protein alpha mRNA, complete cds
/cds(203,2326) /gbL09656 /gi310225
/ugRn.9916 /len2535
0.039118587 transcription factor 12
D84477 Rattus norvegicus mRNA for RhoA, partial cds 0.049476701 plysia ras-related homolog A2
U83895 Rattus norvegicus sec7A mRNA, complete cds
/cds(75,1271) /gbU83895 /gi1800314
/ugRn.10672 /len1399
0.024757689 pleckstrin homology, Sec7 and coiled/coil
domains 1
Z14118cds RNPDGFACE R.norvegicus mRNA for
platelet-derived growth factor receptor alpha
(extracellular domain)
0.039416226 Platelet derived growth factor receptor, alpha
polypeptide
rc_AA859648 UI-R-E0-bs-b-01-0-UI.s1 UI-R-E0 Rattus
norvegicus cDNA clone UI-R-E0-bs-b-01-0-UI 3 similar
to dbj D85429 D85429 Human DNA for heat shock
protein 40, complete cds, mRNA sequence [Rattus
norvegicus]
0.046287981 Similar to heat shock protein 40
U04740 Rattus norvegicus Sprague-Dawley platelet-
activating factor receptor mRNA, complete cds
/cds(119,1144) /gbU04740 /gi470384
/ugRn.10137 /len1301
0.013264912 platelet-activating factor receptor
U90448 RNU90448 Rattus norvegicus CXC chemokine
LIX mRNA, complete cds
0.009327888 CXC chemokine LIX
M15358cds RATMHRTB5 Rat MHC class II RT1.B beta
gene, encoding cell surface glycoprotein beta chain, exon
6
0.039110392 RT1 class II, locus Bb
X95990exon RNC5ARECP R.norvegicus mRNA for C5a
anaphylatoxin receptor
0.020817002 complement component 5, receptor 1
rc_AI170379 EST216305 Rattus norvegicus cDNA, 3 end
/cloneRLUCH58 /clone_end3 /gbAI170379
0.009773891 —/gi3710419 /ugRn.15696 /len688
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U05014_g_at 346.5 P 382.1 P 423.8 P 392.4 P 483.8 P 466 P
M19533mRNA_i_at 1712.7 P 1898.6 P 2055.5 P 1935.6 P 2189.2 P 2296.4 P
X60651mRNA_s_at 91.7 P 125.2 P 65.6 A 143.9 P 218.4 P 241.3 P
rc_AI234604_s_at 1983.6 P 2288.9 P 2195.7 P 2693.9 P 3119.9 P 3384.9 P
rc_AI137862_s_at 181.7 P 221.4 P 211.7 P 220.8 P 252.9 P 278 P
AF081148_s_at 31.4 P 34.8 P 3.9 A 57.8 P 77.4 P 78 P
AJ011115_at 19.6 P 18.4 P 11.6 A 28.7 P 40.6 P 41.3 P
U63923_at 116.6 P 119.9 P 47.5 A 157.1 P 261.1 P 239.9 P
AF004811_at 85 P 115.2 P 51.6 M 179 P 285.7 P 257.5 P
M91466_at 37.2 P 41.8 P 32.6 A 49.6 P 67.8 P 63.4 P
rc_AI639411_at 73.1 P 72.1 P 67.9 P 80 P 88.7 P 92.7 P
L25331_at 249.2 P 348.3 P 267.3 P 415.7 P 409 P 346.3 P
U41845_at 24.7 M 41.5 P 23.7 A 50.8 P 51.7 P 43 P
rc_AI176456_at 1474.4 P 2310.3 P 1100.5 P 4018.3 P 3956.8 P 3067.4 P
L38615_at 27.2 P 49.2 P 14 A 74.9 P 77.9 P 59.9 P
U31598_s_at 313.1 P 468.8 P 235.4 P 535.5 P 617.5 P 569.3 P
M83676_at 126.8 P 162.8 P 127.1 A 189.4 P 200.3 P 183 P
rc_AI235585_s_at 692 P 1209.4 P 464.3 P 1446 P 1607.5 P 1419.2 P
AF033027_at 25.6 P 43.8 P 6.2 A 57.3 P 72.5 P 57.6 P
M21476_s_at 209.2 P 349.8 P 106.4 P 437.4 P 547.1 P 424.7 P
rc_AI237535_s_at 370.6 P 568.4 P 309.8 P 703.9 P 826.8 P 702.5 P
Z18877_s_at 122.5 P 162 P 123 A 195.2 P 222.8 P 189.3 P
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U05014 RNU05014 Rattus norvegicus Sprague/Dawley
PHAS-I mRNA, complete cds
0.036370978 eukaryotic translation initiation factor 4E
binding protein 1
M19533mRNA RATCYCA Rat cyclophilin mRNA,
complete cds
0.030475149 peptidylprolyl isomerase A
X60651mRNA RNSYNDCN Rat mRNA for syndecan 0.034184855 syndecan 1
rc_AI234604 EST231166 Rattus norvegicus cDNA, 3 end
/cloneRLUDC11 /clone_end3 /gbAI234604
/ugRn.3672 /len454
0.01191943 heat shock protein 8
rc_AI137862 UI-R-C0-ik-g-07-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-C0-ik-g-07-0-UI
/clone_end3 /gbAI137862 /ugRn.3293
/len502
0.044226754 mitogen activated protein kinase 14
AF081148 Rattus norvegicus CL2AA mRNA, complete cds 0.015478239 latrophilin 2
AJ011115 RNO011115 Rattus norvegicus mRNA for
endothelial nitric oxide synthase, 5 region, partial
0.015529454 nitric oxide synthase 3, endothelial cell
U63923 RRU63923 Rattus rattus thioredoxin reductase
mRNA, complete cds
0.036337699 thioredoxin reductase 1




M91466 Rattus norvegicus A2b-adenosine receptor
mRNA, complete cds /cds(107,1105) /gbM91466
/gi202587 /ugRn.10428 /len1839
0.024236302 adenosine A2B receptor
Rat mixed-tissue library Rattus norvegicus cDNA clone
rx04714 3 , mRNA sequence [Rattus norvegicus]
0.039351095 P55
L25331 Rattus norvegicus lysyl hydroxylase mRNA,
complete cds /cds(143,2329) /gbL25331
/gi409058 /ugRn.4445 /len2987
0.047904578 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase (lysine hydroxylase)
U41845 Rattus norvegicus putative nuclear pore complex
protein (Npap60) mRNA, complete cds
/cds(320,1465) /gbU41845 /gi1915964
/ugRn.3242 /len2994
0.043171395 nuclear pore associated protein
rc_AI176456 EST220041 Rattus norvegicus cDNA, 3 end
/cloneROVBR96 /clone_end3 /gbAI176456 /
ugRn.6145 /len370
0.013374637 —
L38615 Rattus norvegicus glutathione synthetase mRNA,
complete cds /cds(44,1468) /gbL38615
/gi755063 /ugRn.1692 /len1882
0.025068953 glutathione synthetase
U31598 RNU31598 Rattus norvegicus MHC class II-like
alpha chain (RT1.DMa) mRNA, partial cds
0.035732439 major histocompatibility complex, class II,
DM alpha
M83676 Sprague-Dawley (clone LRB6) RAB12 mRNA, 3
end /cds(0,593) /gbM83676 /gi206530
/ugRn.11021 /len678
0.025264926 RAB12, member RAS oncogene family
rc_AI235585 EST232147 Rattus norvegicus cDNA, 3 end
/cloneROVCT80 /clone_end3 /gbAI235585 /
ugRn.11085 /len384
0.03740925 cathepsin D
AF033027 Rattus norvegicus prenylated SNARE protein
Ykt6p (Ykt6) mRNA, complete cds /cds(0,596)
/gbAF033027 /gi2642347 /ugRn.11358
/len597
0.034513416 prenylated SNARE protein
M21476 RAT5MDA Rat iodothyronine 5 -
monodeiodinase (5 -MD) mRNA, partial cds
0.037715103 prolyl 4-hydroxylase, beta polypeptide
rc_AI237535 EST234097 Rattus norvegicus cDNA, 3 end
/cloneRPLDA30 /clone_end3 /gbAI237535 /
ugRn.6940 /len472
0.024119482 LPS-induced TNF-alpha factor
Z18877 R.norvegicus mRNA for 2 5 oligoadenylate
synthetase /cds(69,1145) /gbZ18877 /gi56789
0.022020341 2’,5’-oligoadenylate synthetase 1, 40/46kDa/ugRn.10383 /len1421
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M74494_g_at 182 P 376.4 P 71.3 P 528.6 P 668.8 P 424.3 P
E01524cds_s_at 104.5 P 126.5 P 111.1 P 140.7 P 160.5 P 136.2 P
D45247_at 584.5 P 871.4 P 658.1 P 945.6 P 1148.4 P 952.1 P
S77528cds_s_at 83.9 P 101.3 P 64.7 A 141.9 P 200.5 P 126 P
rc_AA892260_g_at 141.4 P 149.2 P 155.5 P 191.1 P 214.8 P 173.9 P
AF087944mRNA_s_at260.1 P 336.9 P 139.1 P 684.4 P 857.2 P 544.5 P
X56596_at 268.4 P 370.3 P 192.1 P 589.9 P 768.6 P 500.9 P
rc_AA875665_at 247.9 P 397.8 P 199.8 P 570 P 743.3 P 494.2 P
rc_AI172064_at 3351.5 P 4083.6 P 4195.5 P 4655.5 P 4971 P 4247.8 P
D10874_at 920.1 P 1288 P 1122.4 P 1615.6 P 1797.4 P 1556.8 P
AF065438_at 825.7 P 939.5 P 582.7 P 1376.2 P 1475.3 P 1025 P
L23088_at 137.2 P 143 P 75.9 P 199.1 P 224.4 P 189.3 P
X54467_at 1058.3 P 1112.4 P 855.4 P 1473.1 P 1542.6 P 1389 P
X82396_at 2501.6 P 2741.8 P 2028.7 P 3232.9 P 3644.2 P 3155.4 P
AF087431_at 99.6 P 109.8 P 101.7 P 132.3 P 141.9 P 122.9 P
AF087943_s_at 584.5 P 528.8 P 253.9 P 979.6 P 1240.7 P 775.9 P
Z49761_at 209.2 P 211.6 P 200.2 P 296.7 P 331.5 P 276.5 P
U35774_at 173.4 P 191.8 P 89.7 P 361.7 P 423.3 P 322.3 P
M13979_at 77.1 P 67.1 P 41.2 A 151.6 P 174.7 P 121.3 P
rc_AA955306_at 424 P 398.7 P 386.2 P 629.1 P 633.8 P 559.2 P
J02780_at 632.5 P 696.2 P 398.1 P 1293.6 P 1254.7 P 1064.6 P
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M74494 Rat sodium/potassium ATPase alpha-1 subunit
truncated isoform mRNA, 3 end /cds(0,731)
/gbM74494 /gi205629 /ugRn.2992 /len936
0.043051889 ATPase, Na
/K
 transporting, alpha 1
polypeptide
E01524cds DNA encoding soluble NADPH-cytochrome
P450 redutase
0.036886027 P450 (cytochrome) oxidoreductase
D45247 RATPSRCX Rat mRNA for proteasome subunit
RCX, complete cds
0.041817495 Proteasome (prosome, macropain) subunit,
beta type 5
S77528cds rNFIL-6C/EBP-related transcription factor
[rats, Genomic/mRNA, 1759 nt]
0.046313788 CCAAT/enhancer binding protein (C/EBP),
beta
rc_AA892260 EST196063 Rattus norvegicus cDNA, 3 end
/cloneRKIAO30 /clone_end3 /gbAA892260 /
gi3019139 /ugRn.9526 /len554
0.01841651 Similar to tex261
AF087944mRNA Rattus norvegicus monocyte
differentiation antigen CD14 gene, promoter region and
partial cds
0.015601243 CD14 antigen
X56596 Rat mRNA for MHC class II antigen RT1.B-1
beta-chain /cds(7,798) /gbX56596 /gi57152 /
ugRn.20089 /len1374
0.024561684 RT1 class II, locus Bb
rc_AA875665 UI-R-E0-cn-h-07-0-UI.s1 Rattus norvegicus




rc_AI172064 EST218059 Rattus norvegicus cDNA, 3 end
/cloneRMUBU47 /clone_end3 /gbAI172064
/gi3712104 /ugRn.57 /len509
0.026755839 lectin, galactose binding, soluble 1





 transporting, lysosomal (vacuolar
proton pump) 16 kDa
AF065438 Rattus norvegicus mama mRNA, complete cds
/cds(155,1879) /gbAF065438 /gi3152927 /
ugRn.3251 /len2151
0.047187473 lectin, galactoside-binding, soluble, 3 binding
protein












AF087431 Rattus rattus glycoprotein processing
glucosidase I mRNA, complete cds
0.022296612 glucosidase 1
AF087943 Rattus norvegicus CD14 mRNA, complete cds 0.036342965 CD14 antigen
Z49761 R.norvegicus mRNA for RT1.Ma /cds(23,805)
/gbZ49761 /gi1296988 /ugRn.11298
/len1049
0.010896393 major histocompatibility complex, class II,
DM alpha
U35774 Rattus norvegicus cytosolic branch chain
aminotransferase mRNA, complete cds /cds(62,1297)
/gbU35774 /gi1173633 /ugRn.8273
/len1370
0.009607159 branched chain aminotransferase 1, cytosolic
M13979 Rat brain glucose-transporter protein mRNA,
complete cds /cds(208,1686) /gbM13979
/gi204413 /ugRn.3205 /len2571
0.01240714 solute carrier family 2 (facilitated glucose
transporter), member 1
rc_AA955306 UI-R-A1-ew-b-03-0-UI.s1 Rattus
norvegicus cDNA, 3 end /cloneUI-R-A1-ew-b-03-0-
UI /clone_end3 /gbAA955306 /ugRn.4579 /
len562
0.006124412 —
J02780 Rat tropmyosin (TM-4) mRNA, complete cds /
cds(26,772) /gbJ02780 /gi207503
0.008127395 tropomyosin 4/ugRn.11115 /len900
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U59801_at 22.1 P 22.3 P 10.9 A 45.1 P 44.4 P 35.7 P
X97443_s_at 301.4 P 358.4 P 181.1 P 580.9 P 581.8 P 492.7 P
AFFX_Rat_GAPDH_
M_at
2593.7 P 3016.7 P 2289 P 4160.7 P 4048.5 P 3503.6 P
X96437mRNA_at 123.6 P 136.7 P 115.2 P 225.8 P 223 P 171.1 P
U15550_at 122.6 P 63.5 P 5.9 A 191.4 P 275.6 P 178.7 P
U26595_at 374.5 P 280.5 P 304 P 434.4 P 543.5 P 419.6 P
AB005900_at 91.4 P 56.8 P 64.2 P 121.4 P 165 P 123.8 P
M62642_at 25.9 P 19.9 M 24.1 A 32.2 P 39.9 P 30 P
U12402_at 287 P 231.1 P 232.7 P 316.2 P 380.4 P 331.7 P
M24067_at 649.1 P 273.7 P 337.7 P 1051.8 P 1407 P 758.5 P
U09401_s_at 57.6 P 32.1 P 4.4 A 115.8 P 190.1 P 155.6 P
S61868_at 365.6 P 346.5 P 307 P 499.6 P 648.8 P 503.1 P
rc_AI071531_s_at 145.1 P 99.2 P 66.3 A 267.3 P 432.2 P 288.7 P
D86373_s_at 47.7 P 62.4 P 25 A 85.5 P 128 P 99.7 P
S66024_at 22.5 P 32.3 M 6.9 A 47.7 P 76.6 P 49.8 P
U04835_at 25.4 P 28.6 P 23.7 A 43.7 P 58.6 P 44.9 P
U49930_at 42.2 P 45 P 35.5 P 62.4 P 81.3 P 71.2 P
D86641_at 383.8 P 420.5 P 377.1 P 553.9 P 725.1 P 631.1 P
X69903_at 157.9 P 170.5 P 63.1 A 249.5 P 343.3 P 271.8 P
S56464mRNA_g_at 67 P 58.7 P 11.2 A 93.3 P 133.7 P 109.1 P
AB002086_g_at 469.8 P 415.6 P 547.1 P 510.7 P 483.6 P 474.6 P
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U59801 RNU59801 Rattus norvegicus integrin alpha-M
(Itgam) mRNA, partial cds
0.010932137 integrin alpha M
X97443 R.norvegicus mRNA for transmembrane protein
Tmp21-I /cds(0,611) /gbX97443 /gi1360135
/ugRn.22674 /len706
0.014377536 integral membrane protein Tmp21-I (p23)
R. norvegicus /GENgapd /DB_XREFgb:X02231.1
/DEFRat mRNA for glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) (GAPDH, EC 1.2.1.12).
0.020986944 glyceraldehyde-3-phosphate dehydrogenase
X96437mRNA RNPRG1 R.norvegicus PRG1 gene 0.015268304 immediate early response 3
U15550 RNU15550 Rattus norvegicus tenascin-C mRNA,
partial cds
0.030391377 Tenascin C
U26595 Rattus norvegicus prostaglandin F2a receptor
regulatory protein precursor, mRNA, complete cds /
cds(46,2685) /gbU26595 /gi1054883
/ugRn.6332 /len5825
0.042095775 prostaglandin F2 receptor negative regulator
AB005900 Rattus norvegicus mRNA for endothelial
receptor for oxidized low-density lipoprotein, complete
cds /cds(91,1185) /gbAB005900 /gi3077733
/ugRn.14541 /len3750
0.022729284 oxidised low density lipoprotein (lectin-like)
receptor 1
M62642 Rat (clone pRHx1) hemopexin mRNA, complete
cds /cds(22,1404) /gbM62642 /gi554442
/ugRn.2380 /len1484
0.031337421 hemopexin
U12402 Rattus norvegicus Sprague-Dawley rARL1
mRNA, complete cds /cds(25,570) /gbU12402
/gi529679 /ugRn.11401 /len832
0.038408327 ADP-ribosylation factor-like 1
M24067 Rattus norvegicus plasminogen activator
inhibitor-1 (PAI-1) mRNA, complete cds
/cds(118,1326) /gbM24067 /gi577500
/ugRn.11203 /len3053
0.04231207 serine (or cysteine) proteinase inhibitor,
member 1
U09401 RNU09401 Rattus norvegicus clone p12.3
tenascin mRNA, partial cds
0.010663928 tenascin C
S61868 ryudocanheparan sulfate proteoglycan core
protein [rats, microvascular endothelial cells, mRNA,
2462 nt]
0.021943319 syndecan 4
rc_AI071531 UI-R-C1-ky-b-05-0-UI.s2 Rattus norvegicus
cDNA, 3 end /cloneUI-R-C1-ky-b-05-0-UI
/clone_end3 /gbAI071531 /ugRn.14541
/len451
0.018570682 oxidised low density lipoprotein (lectin-like)
receptor 1
D86373 Rattus norvegicus mRNA for acyl-coenzyme A-
cholesterol acyltransferase, complete cds
/cds(91,1728) /gbD86373 /gi3036904
/ugRn.13213 /len1750
0.025827794 acyl-coenzyme A:cholesterol acyltransferase
S66024 transcriptional repressor CREM [rats, pineal gland,
mRNA, 436 nt]
0.035995281 cAMP responsive element modulator
U04835 Rattus norvegicus CREMdeltaC-G gene,
complete cds /cds(8,460) /gbU04835
/gi1256545 /ugRn.10251 /len607
0.012551525 cAMP responsive element modulator
U49930 Rattus norvegicus ICE-like cysteine protease




D86641 Rattus norvegicus mRNA for FK506-binding
protein 12, complete cds
0.012544648 FK506 binding protein 2 /// FK506-binding
protein 1a
X69903 R.norvegicus mRNA for interleukin 4 receptor
/cds(9,2411) /gbX69903 /gi56390
/ugRn.10471 /len2450
0.026783348 interleukin 4 receptor
S56464mRNA S56463S2 HKIIhexokinase II [rats,
epididymal fat pad, mRNA Partial, 1456 nt, segment 2 of
2]
0.035340531 —
AB002086 Rattus norvegicus mRNA for p47, complete cds
/cds(108,1220) /gbAB002086 /gi2285789 /
0.047110266 p47 proteinugRn.2771 /len1451
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AF072892_s_at 587.7 P 326.8 P 455.4 P 1056.8 P 781.5 P 794.5 P
rc_AA893846_at 1160 P 503.4 P 644.8 P 2226.9 P 1757.5 P 1426.2 P
L01624_at 316.5 P 218.5 P 289.1 P 581.2 P 387.1 P 464.3 P
U04319_at 77.6 P 51.8 P 90.2 A 150.5 P 120.4 P 114.4 P
Z11504cds_at 45.8 P 36.9 P 50.3 P 76.9 P 67.8 P 58.5 P
L32132_at 324.6 P 269 P 386.2 P 610 P 506.1 P 448 P
J02722cds_at 229.1 P 172.8 P 210 P 632.2 P 429.7 P 487.4 P
S82911_at 122 P 104.6 P 164.2 P 314.4 P 248.3 P 251.9 P
U22414_at 210.3 P 85.5 P 239.6 P 515.4 P 316 P 326.6 P
D86711_at 90.2 P 89.8 P 125.3 P 139.5 P 111.1 P 116 P
U17035_s_at 43.1 P 33.5 P 76.5 M 114.3 P 73 P 74.5 P
rc_AA955477_g_at 120.4 P 121.7 P 152.2 P 182 P 165.7 P 134.3 P
M58364_at 84.2 P 107.8 P 125.7 P 222.7 P 183.4 P 142.8 P
D10106_s_at 52.8 P 72.7 P 70 A 118.7 P 113.3 P 87.9 P
AB017596_at 27.1 A 38 P 48 A 90.7 P 88.7 P 59.8 P
X17163cds_s_at 38.3 P 71.4 P 81.9 P 148.3 P 167.5 P 102.3 P
X02601_at 118.7 P 108 P 175.9 P 391.6 P 458.6 P 215.9 P
rc_AA818604_s_at 16.1 P 20.5 P 18.7 A 66.4 P 76.3 P 41.6 P
rc_AA892791_at 170.2 P 217.3 P 198.9 P 405 P 406.5 P 266 P
X12459_at 45 P 64.1 P 48.4 A 234.1 P 256.1 P 113.3 P
rc_AI176710_at 18.5 P 23.5 P 21.8 A 72.9 P 71.5 P 32.4 P
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AF072892 Rattus norvegicus versican V3 isoform
precursor, mRNA, complete cds
0.018279444 chondroitin sulfate proteoglycan 2 (versican)




L01624 Rattus norvegicus serum and glucocorticoid-
regulated kinase (sgk) mRNA, complete cds
/cds(65,1357) /gbL01624 /gi294636
/ugRn.4636 /len2435
0.021892071 serum/glucocorticoid regulated kinase
U04319 Rattus norvegicus Fit-1S (Fit-1) mRNA, complete
cds /cds(201,1211) /gbU04319 /gi488278 /
ugRn.10072 /len2586
0.009300767 interleukin 1 receptor-like 1
Z11504cds RRNPV1R R.rattus mRNA for NPY-1 receptor 0.00982065 Neuropeptide Y receptor Y1
L32132 Rat lipopolysaccharide binding protein mRNA,
complete cds /cds(227,1672) /gbL32132
/gi510714 /ugRn.1404 /len2622
0.010120158 lipopolysaccharide binding protein
J02722cds RATHOXA Rat heme oxygenase gene,
complete cds
0.005637314 heme oxygenase (decycling) 1
S82911 rHoxrHox protein [rats, ROS 17/2.8
osteosarcoma cell line, mRNA, 1375 nt]
0.002011691 paired related homeobox 1
U22414 Rattus norvegicus macrophage inflammatory
protein-1alpha mRNA, complete cds /cds(69,347)
/gbU22414 /gi790632 /ugRn.10139 /len755
0.03695392 chemokine (C-C motif) ligand 3
D86711 D86711 Rattus norvegicus cDNA /gbD86711
/gi1549215 /ugRn.4240 /len994
0.022332009 —
U17035 RRU17035 Rattus sp. (mob-1) mRNA, complete
cds
0.048921717 chemokine (C-X-C motif) ligand 10
rc_AA955477 UI-R-A1-ex-f-01-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-A1-ex-f-01-0-UI
/clone_end3 /gbAA955477 /ugRn.8789
/len394
0.03929932 Similar to Expressed sequence AI874665
M58364 Rat GTP cyclohydrolase I mRNA, complete cds
/cds(127,852) /gbM58364 /gi204536
/ugRn.5933 /len1016
0.02050961 GTP cyclohydrolase 1
D10106 RATPDGFA Rat mRNA for platelet-derived
growth factor A chain
0.013422874 platelet derived growth factor, alpha
AB017596 Rattus norvegicus PC1 mRNA for plasma cell
membrane glycoprotein, partial cds
0.012604414 ectonucleotide
pyrophosphatase/phosphodiesterase 1
X17163cds RSJUNAP1 Rat c-jun oncogene mRNA for
transcription factor AP-1
0.020453371 v-jun sarcoma virus 17 oncogene homolog
(avian)
X02601 Rat mRNA for 53 kD polypeptide induced by
growth factors (EGF) and oncogenes (H-ras; src;
polyoma middle T) /cds(57,1484) /gbX02601 /
gi57460 /ugRn.10435 /len1771
0.034007216 matrix metalloproteinase 3
rc_AA818604 UI-R-A0-bc-h-02-0-UI.s1 Rattus
norvegicus cDNA, 3 end /cloneUI-R-A0-bc-h-02-0-
UI /clone_end3 /gbAA818604 /gi2889343 /
ugRn.1950 /len516
0.014227834 heat shock 70kD protein 1B /// heat shock
70kD protein 1A
rc_AA892791 EST196594 Rattus norvegicus cDNA, 3 end
/cloneRKIAX34 /clone_end3 /gbAA892791 /
gi3019670 /ugRn.7320 /len635
0.023015033 excision repair cross-complementing repair
deficiency, complementation group 1
X12459 Rat mRNA for argininosuccinate synthetase (EC
6.3.4.5) /cds(14,1252) /gbX12459 /gi55766
/ugRn.5078 /len1495
0.028600961 arginosuccinate synthetase
rc_AI176710 EST220303 Rattus norvegicus cDNA, 3 end
/cloneROVBV80 /clone_end3 /gbAI176710 /
0.042676571 nuclear receptor subfamily 4, group A,
member 3ugRn.10410 /len632
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U90610_at 339.1 P 302.1 P 226.8 P 774 P 946.9 P 555.5 P
rc_AA800175_at 210.4 P 218.8 P 238.6 P 282.7 P 295.9 P 230.8 P
rc_AA892859_at 226.9 P 155.3 P 226.1 P 287.6 P 291.7 P 238.1 P
X96437mRNA_g_at 185.2 P 119.1 P 182.3 P 236.1 P 262.1 P 214.4 P
S61868_g_at 572.9 P 374 P 618 P 934.1 P 924.2 P 721 P
AF052695_at 102.3 P 91.8 P 93 P 158.7 P 151.1 P 111.9 P
D63665_at 159.6 P 136.4 P 136 P 283.3 P 268.6 P 188.3 P
U87627_at 139 P 128.2 P 114.6 P 337.8 P 328.1 P 222.5 P
rc_AI236601_at 184.5 P 148.6 P 149.5 P 337.6 P 344.8 P 250.7 P
X07266cds_s_at 83.1 P 39.5 A 50.8 A 250.2 P 243.5 P 149.4 P
AF036537_at 106.1 P 87.2 P 105.6 A 186.2 P 182.5 P 147.6 P
U90610_g_at 289.4 P 226.6 P 273.4 P 488.6 P 514.1 P 374.2 P
rc_AA891838_at 110.9 P 99.1 A 126.4 A 137.1 P 141.3 P 120.7 M
rc_AA893860_at 288.3 P 225.5 P 284.7 P 399.6 P 389.2 P 335 P
rc_AA818951_at 2793.2 P 2060.7 P 2219.4 P 3566.5 P 3527.2 P 3015.6 P
rc_AI169327_g_at 2996.5 P 1613.1 P 1765.3 P 4043.6 P 3781.6 P 3065.5 P
M54926_at 2019.7 P 1579.4 P 1495.9 P 2560.9 P 2799.6 P 2195.7 P
S87522_g_at 1091.8 P 856.7 P 985.4 P 1229 P 1284.1 P 1137.1 P
rc_AA893173_at 393.5 P 348.5 P 360.1 P 439.2 P 460.3 P 437.1 P
U28938_at 233.8 P 206 P 184.4 P 308.3 P 313.4 P 286 P
M23697_at 560.4 P 418.5 P 364.4 P 817.3 P 788 P 704.8 P
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U90610 Rattus norvegicus CXC chemokine receptor
(CXCR4) mRNA, complete cds /cds(0,1049)
/gbU90610 /gi1906612 /ugRn.5289
/len1050
0.018261589 chemokine (C-X-C motif) receptor 4
rc_AA800175 EST189672 Rattus norvegicus cDNA, 3 end
/cloneRHEAM08 /clone_end3 /gbAA800175
/gi2863130 /ugRn.6291 /len601
0.040286547 protein (peptidyl-prolyl cis/trans isomerase)
NIMA-interacting 1
rc_AA892859 EST196662 Rattus norvegicus cDNA, 3 end
/cloneRKIAY19 /clone_end3 /gbAA892859 /
gi3019738 /ugRn.8137 /len568
0.035057433 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 3
X96437mRNA RNPRG1 R.norvegicus PRG1 gene 0.022175736 immediate early response 3
S61868 ryudocanheparan sulfate proteoglycan core
protein [rats, microvascular endothelial cells, mRNA,
2462 nt]
0.013830246 syndecan 4
AF052695 Rattus norvegicus cell cycle protein p55CDC
gene, complete cds /cds(192,1691) /gbAF052695
/gi3088631 /ugRn.9262 /len1777
0.035676393 cell cycle protein p55CDC
D63665 Rat mRNA for novel G protein-coupled P2
receptor, complete cds /cds(439,1425) /gbD63665
/gi1066007 /ugRn.10671 /len1922
0.026969924 pyrimidinergic receptor P2Y, G-protein
coupled, 6
U87627 Rattus norvegicus putative monocarboxylate




rc_AI236601 EST233163 Rattus norvegicus cDNA, 3 end
/cloneROVDI22 /clone_end3 /gbAI236601 /
ugRn.2277 /len625
0.011516373 Similar to heat shock protein 105 kDa alpha
X07266cds RRG33A Rat mRNA for gene 33 polypeptide 0.011190785 Similar to Mitogen-inducible gene 6 protein
homolog (Mig-6) (Gene 33 polypeptide)
AF036537 Rattus norvegicus homocysteine respondent
protein HCYP2 mRNA, complete cds
0.005282392 receptor-interacting serine-threonine kinase 3
U90610 Rattus norvegicus CXC chemokine receptor
(CXCR4) mRNA, complete cds /cds(0,1049)
/gbU90610 /gi1906612 /ugRn.5289
/len1050
0.012618133 chemokine (C-X-C motif) receptor 4
rc_AA891838 EST195641 Rattus norvegicus cDNA, 3 end
/cloneRKIAH44 /clone_end3 /gbAA891838 /
gi3018717 /ugRn.24892 /len537
0.017783131 ribosomal protein P0-like protein; 60S acidic
ribosomal protein PO




rc_AA818951 UI-R-A0-as-e-04-0-UI.s1 Rattus norvegicus
cDNA, 3 end /cloneUI-R-A0-as-e-04-0-UI
/clone_end3 /gbAA818951 /gi2888537
/ugRn.1556 /len474
0.029841991 pyruvate kinase, muscle
rc_AI169327 EST215162 Rattus norvegicus cDNA, 3 end
/cloneRKIBQ31 /clone_end3 /gbAI169327 /
gi3705635 /ugRn.6841 /len644
0.04661103 tissue inhibitor of metalloproteinase 1




S87522 leukotriene A4 hydrolase [rats, mesangial cells,
mRNA, 1925 nt]
0.040762553 Similar to Leukotriene A-4 hydrolase (LTA-4
hydrolase) (Leukotriene A(4) hydrolase)
rc_AA893173 EST196976 Rattus norvegicus cDNA, 3 end
/cloneRKIBD12 /clone_end3 /gbAA893173 /
gi3020052 /ugRn.2547 /len606
0.031477751 vacuolar protein sorting 29 isoform 2;
vacuolar sorting protein VPS29/PEP11
U28938 Rattus norvegicus protein tyrosine phosphatase
D30 mRNA, complete cds /cds(62,3712)
/gbU28938 /gi1144001 /ugRn.10163
/len4871
0.016306037 protein tyrosine phosphatase, receptor type, O
M23697 Rat tissue-type plasminogen activator (t-PA)
mRNA, complete cds /cds(31,1710) /gbM23697
0.014743514 plasminogen activator, tissue/gi530159 /ugRn.1002 /len2445
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64.4 P 48.2 P 52.1 A 93.6 P 89.5 P 87.6 P
M95768_at 188.3 P 161.5 P 161.9 P 250.9 P 225.7 P 204.4 P
X57764_s_at 23.9 P 45.7 P 36.6 A 70.2 P 100.7 P 61.4 P
U04808_at 27.4 P 33.8 M 39.4 A 53.2 P 79.3 P 49.3 P
C07012_f_at 319.5 P 378.5 P 508.6 P 543.6 P 695.1 P 468.1 P
U50185_at 23.8 P 37.7 P 47.1 A 57.7 P 77 P 50.7 P
X05566_i_at 1457.9 P 1529.1 P 2008.6 P 1988 P 2179.2 P 1951.4 P
L02530_at 99.9 P 128.5 P 162.3 P 157.2 P 196.1 P 159.2 P
AF039891_s_at 56.4 A 74.9 P 98.5 A 99.4 M 128.1 P 104.9 P
A03913cds_s_at 109.4 P 182.9 P 210.1 P 281.4 P 375 P 306.7 P
U83896_at 137.5 P 198.2 P 221 P 228.3 P 257.6 P 210.3 P
AB017188_g_at 382.5 P 402.4 P 581.4 P 461.9 P 503.8 P 479 P
U09361_s_at 117.6 P 60.3 P 117.8 A 241.2 P 358.9 P 243.3 P
M32062_at 892.4 P 725.4 P 1044.8 P 1286.4 P 1780.5 P 1386.9 P
rc_AA892417_at 131.3 P 114.9 P 171.8 P 151.5 P 178.4 P 155 P
rc_AA899935_at 76.1 P 64.4 P 90.6 A 83.6 P 104.2 P 86.8 P
U77349cds_at 22.5 P 11.9 P 19.5 A 26.3 P 37.8 P 32.4 P
D26393exon_s_at 188.2 P 131 P 211.7 P 214.8 P 288.4 P 247.5 P
rc_AA799469_at 164.8 P 139.1 P 193.3 P 169.9 P 195.9 P 182.8 P
X06564_at 125.5 P 116.9 P 183.9 A 188.2 P 224.2 P 166.5 P
rc_AA800005_at 837.8 P 755 P 1114.9 P 1008.4 P 1021.8 P 944.2 P
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U03699completeSeq Rattus norvegicus Sprague Dawley
inducible nitric oxide synthase (NOS) mRNA, complete
cds /cdsUNKNOWN /gbU03699 /gi430718
/ugRn.10400 /len3943
0.005271729 nitric oxide synthase 2, inducible
M95768 Rattus norvegicus di-N-acetylchitobiase mRNA,
complete cds /cds(0,1103) /gbM95768
/gi203452 /ugRn.11199 /len1616
0.03289604 chitobiase, di-N-acetyl-
X57764 Rat mRNA for ET-B endothelin receptor
/cds(203,1528) /gbX57764 /gi56122
/ugRn.11412 /len1892
0.031361675 endothelin receptor type B
U04808 Rattus norvegicus Sprague-Dawley putative G-




C07012 C07012 Rat pancreatic islet cDNA Rattus
norvegicus cDNA similar to cyclophilin c, mRNA
sequence [Rattus norvegicus]
0.046666853 lectin, galactoside-binding, soluble, 3 binding
protein
U50185 RNU50185 Rattus norvegicus kidney protein
phosphatase 1 myosin binding subunit mRNA, partial
cds
0.033664212 —
X05566 Rat mRNA for myosin regulatory light chain
(RLC) /cds(69,587) /gbX05566 /gi57086
/ugRn.6021 /len910
0.003833286 Myosin regulatory light chain
L02530 Rattus norvegicus Drosophila polarity gene
(frizzled) homologue mRNA, complete cds
/cds(78,1790) /gbL02530 /gi310114
/ugRn.9095 /len1912
0.028602223 frizzled homolog 2 (Drosophila)
AF039891 Rattus norvegicus aminopeptidase N (APN)
mRNA, partial cds
0.020133263 Aminopeptidase N (APN)
A03913cds R.norvegicus mRNA for glia-derived neurite-
promoting factor (GdNPF)
0.009501821 Serine (or cysteine) proteinase inhibitor, clade
E, member 2
U83896 Rattus norvegicus sec7B mRNA, complete cds
/cds(187,1389) /gbU83896 /gi1800316
/ugRn.3732 /len1561
0.041353368 pleckstrin homology, Sec7 and coiled/coil
domains 2
AB017188 Rattus norvegicus mRNA for antisecretory
factor, complete cds
0.043397667 proteasome (prosome, macropain) 26S
subunit, non-ATPase, 4
U09361 RNU09361 Rattus norvegicus clone p17.1
tenascin mRNA, partial cds
0.012355181 tenascin C
M32062 Rat Fc-gamma receptor mRNA, complete cds /
cds(49,852) /gbM32062 /gi204114
/ugRn.6050 /len1341
0.015717579 Fc receptor, IgG, low affinity III
rc_AA892417 EST196220 Rattus norvegicus cDNA, 3 end




norvegicus cDNA, 3 end /cloneUI-R-E0-dh-h-10-0-
UI /clone_end3 /gbAA899935 /gi3035289 /
ugRn.15002 /len407
0.049213936 platelet-activating factor acetylhydrolase alpha
2 subunit (PAF-AH alpha 2)
U77349cds RNU77349 Rattus norvegicus chemokine
receptor CCR2 gene, complete cds
0.028435908 chemokine receptor CCR2 gene
D26393exon RATHK2 Rat HK2 gene for type II
hexokinase, exon1 and promoter region
0.033448597 hexokinase 2




X06564 Rat mRNA for 140-kD NCAM polypeptide
/cds(208,2784) /gbX06564 /gi56736
/ugRn.11283 /len3170
0.028903862 neural cell adhesion molecule 1
rc_AA800005 EST189502 Rattus norvegicus cDNA, 3 end
/cloneRHEAI20 /clone_end3 /gbAA800005 /
0.018338002 CD151 antigengi2862960 /ugRn.1465 /len628
